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INTRODUCTION 
 
The skin is the largest organ of the body, accounting for more than 10% of body mass, 
and the one that enables the body to interact most intimately with its environment. The skin 
consists of four layers: the stratum corneum (nonviable epidermis), the remaining layers of 
the epidermis (viable epidermis), dermis, and subcutaneous tissues. There are also several 
associated appendages: hair follicles sweat ducts, apocrine glands, and nails.
 1 
Many agents are applied to the skin either deliberately or accidentally, with either 
beneficial or deleterious outcomes and the mechanism was showed in Fig. 1. The use of 
topical products was evident in ancient times, and there are reports of systemic benefits of 
topical anti-infective and hormonal agents in the 1940s. Modern transdermal patch 
technology was introduced in the late 1970s. The main interests in dermal absorption 
assessment are in the application of compounds to the skin  
 For local effects in dermatology (e.g., corticosteroids for dermatitis)  
 For transport through the skin for systemic effects (e.g., nicotine patches for smoking 
cessation)  
 For surface effects (e.g., sunscreens, cosmetics, and anti-infective); To target deeper 
tissues (e.g., Non-steroidal anti-inflammatory agents [NSAIDs] for muscle 
inflammation)  
 Unwanted absorption (e.g., solvents in the workplace, agricultural chemicals, or 
allergens).  
 
Fig. 1 Mechanism of drug through by transdermal delivery 
The skin became popular as a potential site for systemic drug delivery because it was 
thought to  
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 Avoid the problems of stomach emptying, pH effects, and enzyme deactivation 
associated with gastrointestinal passage  
 To avoid hepatic first-pass metabolism  
 To enable control of input, as exemplified by termination of delivery through removal 
of the device 
Delivery of solutes through the skin is associated with various difficulties, such as  
 The variability in percutaneous absorption owing to site, disease, age, and species 
differences  
 The skin‘s ‗‗first-pass‘‘ metabolic effect 
 The reservoir capacity of the skin  
 Irritation and other toxicity caused by topical products 
 Heterogeneity and indelibility of the skin in both turnover and metabolism 
 Inadequate definition of bioequivalence criteria 
 An incomplete understanding of the technologies that may be used to facilitate or 
retard percutaneous absorption. 
 
GROSS STRUCTURE AND FUNCTION OF THE SKIN 
It needs to be emphasized that the protection, homeostatic, and sensing functions of 
the skin are both overlapping and integrated. For instance, barrier properties to a chemical 
entity involves resistance to its entry (barrier provided by stratum corneum), metabolism for 
that proportion of entity bypassing the stratum corneum (in viable epidermis), sensing of and 
attention to damage caused by entry (inflammatory mediator release in epidermis, with 
involvement of dermis), and removal of entity from site by dermal blood supply and 
distribution into those body organs specifically responsible for elimination of the entity by 
metabolism (liver) and excretion (kidney). Heat regulation occurs through the use of the 
subcutaneous fat pad, physiological regulation of blood flow to affect, for instance, heat loss 
by vasodilation, and cooling by perspiration. 
A. The Epidermis 
The epidermis performs a number of functions, as shown in Fig. 2, one of the most 
important being the generation of the stratum corneum. The stratum corneum is the 
heterogeneous outermost layer of the epidermis and is approximately 10–20 _m thick. It is 
nonviable epidermis and consists, in a given cross-section, of 15–25 flattened, stacked, 
hexagonal, and cornified cells embedded in a mortar of intercellular lipid. Each cell is 
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approximately 40 mm in diameter and 0.5 mm thick. The thickness varies, however, and may 
be a magnitude of order larger in areas such as the palms of the hand and soles of the feet, 
areas of the body associated with frequent direct and substantial physical interaction with the 
physical environment. Each stratum corneum cell is composed mainly of insoluble bundled 
keratins (_70%) and lipid (_20%) encased in a cell envelope, accounting for about 5% of the 
stratum corneum weight. The intercellular region consists mainly of lipids and desmosomes 
for coenocyte cohesion. The barrier function is further facilitated by the continuous 
desquamation of this horny layer with a total turnover of the stratum corneum occurring once 
every 2–3 weeks. The cells of the stratum corneum originate in the viable epidermis and 
undergo many morphological changes before desquamation. Thus the epidermis consists of 
several cell strata at varying levels of differentiation. The origins of the cells of the epidermis 
lie in the basal lamina between the dermis and viable epidermis. In this layer there are 
melanocytes, Langerhans cells, and two major keratinic cell types: the first functioning as 
stem cells having the capacity to divide and produce new cells; the second serving to anchor 
the epidermis to the basement membrane. 
The basement membrane is 50–70 nm thick and consists of two layers—the lamina 
dense and lamina Lucida—which comprise mainly proteins, such as type IV collagen, 
laminin, nidogen, and fibronectin. Type IV collagen is responsible for the mechanical 
stability of the basement membrane, whereas laminin and fibronectin are involved with the 
attachment between the basement membrane and the basal keratinocytes. 
B. The Dermis 
In Fig. 2 the dermis, a critical component of the body, not only provides the nutritive, 
immune, and other support systems for the epidermis, through a thin papillary layer adjacent 
to the epidermis, but also plays a role in temperature, pressure, and pain regulation. The main 
structural component of the dermis is referred to as a coarse reticular layer. The dermis is 
about 0.1–0.5 cm thick and consists of collagenous fibers (70%), providing a scaffold of 
support and cushioning, and elastic connective tissue, providing elasticity, in a semigel 
matrix of muco-polysaccharides. In general, the dermis has a sparse cell population. The 
main cells present are the fibroblasts, which produce the connective tissue components of 
collagen, laminin, fibronectin, and vitronectin; mast cells, which are involved in the immune 
and inflammatory responses; and melanocytes involved in the production of the pigment 
melanin. Contained within the dermis is an extensive vascular network providing for the skin 
nutrition, repair, and immune responses and, for the rest of the body, heat exchange, immune 
response, and thermal regulation. The blood flow rate to the skin is about 0.05 mL min_1 
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cc_3 of skin, providing a vascular exchange area equivalent to that of the skin surface area. 
Skin blood vessels derive from those in the subcutaneous tissues, with an arterial network 
supplying the papillary layer, the hair follicles, the sweat and apocrine glands, the 
subcutaneous area, as well as the dermis itself. These arteries feed into arterioles, capillaries, 
venules, and, thence, into veins. Of particular importance in this vascular network is the 
presence of arterio venous anastomoses at all levels in the skin. 
The lymphatic system is an important component of the skin in regulating its interstitial 
pressure, mobilization of defense mechanisms, and in waste removal. It exists as a dense, flat 
meshwork in the papillary layers of the dermis and extends into the deeper regions of the 
dermis. Also present in the dermis are a number of different types of nerve fibers supplying 
the skin, including those for pressure, pain, and temperature. 
 
 Fig. 2 T.S. of the Skin 
 
C. The Sub-cutis 
Fig. 2 shows the deepest layer of the skin is the subcutaneous tissue or hypodermis. 
The hypodermis acts as a heat insulator, a shock absorber, and an energy storage region. This 
layer is a network of fat cells arranged in lobules and linked to the dermis by interconnecting 
collagen and elastin fibers. As well as fat cells (possibly 50% of the body‘s fat), the other 
main cells in the hypodermis are fibroblasts and macrophages. One of the major roles of the 
hypodermis is to carry the vascular and neural systems for the skin. It also anchors the skin to 
underlying muscle. Fibroblasts and adipocytes can be stimulated by the accumulation of 
interstitial and lymphatic fluid within the skin and subcutaneous tissue. 
D. Skin Appendages 
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There are four skin appendages: the hair follicles with their associated sebaceous 
glands, eccrine sweat glands, apocrine sweat glands, and the nails showed in Fig 2. Each 
appendage has a different function as outlined in Table 1. 
 
Appendages 
Parameter 
Hair follicle and 
sebaceous gland 
Eccrine gland Apocrine gland Nails 
Function 
Protection (hair) 
and lubrication 
(serum) 
Cooling 
Vestigial 
secondary sex 
gland 
Protection 
Distribution Most of the body Most of the body 
Axillae, nipples, 
anogenetal 
Ends of fingers 
and toes 
Average/Cm
2 
57-100 100-200 Variable - 
Fractional 
area 
2.7×10
3 
10
-4 
Variable - 
Secretions Sebum 
Sweat (dilute 
saline) 
―Milk‖ protein, 
lipoproteins, 
lipid 
- 
Secretions 
stimulated By 
Heat (minor) Heat, cholinergic Heat - 
Biochemical 
innervation of 
gland 
response 
- Cholinergic Cholinergic - 
Control Hormonal 
Sympathetic 
nerves 
Sympathetic 
nerves 
- 
 
Table 1: Appandages of the Skin 
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1, 2 
Hydrogels are hydrophilic polymeric network of three dimensional cross linked structures 
that absorb substantial amount of water5. Cross linking facilitates insolubility in water 
because of ionic interaction and hydrogen bonding11. It also provides required mechanical 
strength and physical integrity to the Hydrogels. Thus, hydrogels can imbibe water nearly 10-
20 times its molecular weight and hence become swollen. Some examples of Hydrogels 
include contact lenses, wound dressing, super absorbents. 
 
BENEFITS 
 Biocompatible 
 Can be injected 
 Easy to modify 
 Timed release of growth factors and other nutrients to ensure proper tissue growth 
 Entrapment of microbial cells within polyurethane hydrogel beads with the advantage of 
low toxicity 
 Environmentally sensitive hydrogels have the ability to sense changes of pH, 
temperature or the concentration of metabolite and release their load as result of such a 
change. 
 Natural hydrogel materials are being investigated for tissue engineering, which include 
garose, methylcellulose, hylaronan, and other naturally derived polymers. 
 
LIMITATIONS 
 High cost. 
 Low mechanical strength 
 Difficult to load 
 Difficult to sterilize 
 Nonadherent 
 In contact lenses - lens deposition, hypoxia, dehydration and red eye reactions20-24 
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CLASSIFICATION 
1. On the basis of the nature of the cross linked junctions20 
a. Chemically cross-linked networks having permanent junctions. 
b. Physical networks have transient junctions arising from polymer chain entanglements or 
physical interactions 
 
S. No Characteristics Natural origin Synthetic polymers 
1 Preparation By using natural polymer By chemical polymerization 
2 Advantages -Biocompatible 
-Biodegradable 
-Supports cellular activities 
-Inherent bioactive properties 
absent 
3 Disadvantages -Does not possess sufficient 
mechanical properties 
-May contain pathogen 
-Evoke immune and responses 
 
               ______________ 
4 Examples -Properties like collagen and 
gelatin 
-Polysaccharides like alginate 
and agarose 
-Acrylic acid 
-Hydroxy-ethyl-methacrylate 
(HEMA) 
-vinyl acetate 
-Meth acrylic acid (MAA) 
 
Preparation of hydrogels 
1. Use of cross linkers 
 Copolymerization of monomers using multifunctional co-monomer, which acts as cross 
linking agent, chemical initiator initiates the polymerization reaction which can be carried 
out in bulk, solution or suspension. 
 Cross linking of linear polymers by irradiation or by chemical compounds. Monomers 
used here contain an ionizable group that can be ionized or can undergo a substitution 
reaction after the polymerization is completed. Thus, the hydrogels synthesized may 
contain weakly acidic groups like carboxylic acids or weakly basic groups like substituted 
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amines or a strong acidic and basic group like sulfonic acid and quaternary ammonium 
compounds.  
 Cross linkers incorporated are glutaraldehyde, calcium chloride and oxidized konjac 
lucomannan (DAK). They impart sufficient mechanical strength to the polymers and thus 
prevent burst release of the medicaments. 
2. Isotatic Ultra High Pressure (IUHP) 
Suspension of natural biopolymers (e.g.-starch) are subjected to ultra-high pressure of 
300-700 MP n  for 5 or 20 minutes in a chamber which brings about changes in the 
morphology of the polymer (i.e. Gelatinization of starch molecules occur).Temperature in the 
chamber varies from 40 to 52OC30. 
3. Use of Nucleophilic substitution reaction 
A pH and temperature sensitive hydrogel viz. hydrogel of N-2-dimethylamino-ethyl-
methacrylamide (DMAEMA) has been prepared using nucleophilic substitution reaction 
between methacyloyl chloride and 2-dimethylamino ethylamine31. 
4. Use of gelling agent 
Gelling agents like glycophosphate1-2propanediol, glycerol, trehalose, mannitol etc. 
have been used in the preparation of hydrogels. However, presence of negative charged 
moieties and turbidity are the problems associated with the method. 
5. Use of irradiation and freeze thawing 
Irradiation method is suitable as well as convenient but the processing is costly along 
with the poor mechanical strength of the product .Freeze thawing method imparts sufficient 
mechanical strength and stability to the hydrogels except that they are opaque in appearance 
with little swelling capacity. However, hydrogels prepared from microwave irradiation are 
more porous than conventional methods. 
6. Synthesis of hydrogel in industry 
Formulation of monomer along with initiators and additives lead to polymerization 
which forms the gel. The gel is dried, sieved and mixed with other additives and post 
treatment is done if needed.  
 
DESIGN CRITERIA FOR HYDROGELS IN DRUG DELIVERY FORMULATIONS 
Nature of material and network fabrication governs the rate and mode of drug release 
from hydrogel matrices. There are various design criteria for drug that must be evaluated 
before hydrogel fabrication and drug loading. These criteria play a vital role in Mathematical 
modeling of drug release. Design criteria for hydrogels in drug delivery formulations are 
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shown in the Table 3: Design criteria for hydrogels Hydrogel formulation even designed 
with proper physical and transport properties, may still fail to show therapeutic effect when 
implanted in vivo due to a localized inflammatory response. Fibrous capsule formed around 
the delivery device gives rise to additional diffusion barriers that may limit drug release rates 
while increased proteolysis activity may increase rates of matrix and drug degradation. Thus, 
proper material selection, fabrication process and surface texture are important parameters in 
designing biocompatible hydrogel formulations for controlled release. Drug incorporation 
into hydrogel device can be achieved by one of the following methods.  
1. Hydrogels Drug Uptake Release Mechanism 
Inert hydrogels diffusion and/or gel swelling Hydrogel containing drug –binding 
ligands drug-polymer interaction and diffusion 
2. In-situ Loading 
Drug or drug polymer conjugates are mixed with polymer precursor solution and 
hydrogel network formation and drug encapsulation are achieved simultaneously. Here 
release of drugs occurs through diffusion, hydrogel swelling, reversible drug-polymer 
interaction, degradation of labile covalent bonds. 
 
DRUG RELEASE MECHANISMS FROM HYDROGEL DEVICES 
Hydrogels imbibe more water than 90% of their weight due to hydrophilicity, thus 
differing in their release mechanisms from hydrophobic polymers. Various models have been 
developed to predict the release of an active agent from a hydrogel device as a function of 
time. These models are based on the rate limiting step for controlled release and are divided 
into three categories viz. 
 Diffusion controlled 
 Swelling controlled 
 Chemically controlled 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Department of Pharmaceutics, Nandha college of Pharmacy, Erode.                                         Page 10 
 
DIFFUSION CONTROLLED 
It is most widely applicable mechanism relating to drug release. Fick‘s law of 
diffusion is commonly used in modeling this release. 
S. No Hydrogels Drug diffusion coefficients 
1 Porous hydrogels-pore size >>> molecular 
dimensions of the drug 
Related to porosity 
2 Non- Porous hydrogels- porous gels with 
pore sizes comparable to the drug molecular 
size.
34, 35 
Decreases due to steric hindrance 
from polymer chains with in cross 
linked networks. 
 
SWELLING CONTROLLED 
It occurs when diffusion of drug is faster than hydrogel swelling. In this condition the 
modeling of drug involves moving boundary, where molecules are released at the interface of 
the rubbery and glassy phases of swollen hydrogels. Transition occurs from a glassy state 
where entrapped molecules remain immobile to a rubbery state where molecules rapidly 
diffuse. Release of small molecule drugs from HPMC hydrogel tablets are based on this 
mechanism. For example, Methocel matrices (a combination of methylcellulose and HPMC) 
from Dow chemical Company prepare swelling controlled drug delivery formulations. 
CHEMICALLY CONTROLLED 
It characterizes molecule release based on reactions occurring within a delivery 
matrix. Most commonly occurring reactions are- 
 Cleavage of polymer chains via hydrolytic or enzymatic degradation. 
 Reversible or irreversible reactions occurring between the polymer network and releasable 
drug.  
It can be categorized on the basis of reactions occurring during drug release. 
Purely–kinetic – controlled release 
Polymer degradation (bond cleavage) is the rate determining step while diffusion 
contributes almost negligible to the drug release.  
It is of two types viz. 
 Pendant chain (prodrugs) 
 Surface eroding systems 
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In pendent chain systems, drugs are covalently linked to the hydrogel network device 
through cleavable spacers and drug release is controlled by the rate with which spacer bond 
cleavage occurs. In specific applications where a more targeted delivery approach is desired, 
it is advantageous to design enzymatically cleavable spacer bonds. In surface eroding 
systems, drug release is mediated by the rate of surface erosion of the polymer matrix. In 
hydrophobic polymer networks, surface erosion occurs when the rate of water transport into 
the polymer is much slower than the rate of bond hydrolysis. Nevertheless due to the 
inherently high water content of hydrogels, surface erosion occurs slowly in enzymatic 
degradation systems where the transport of enzyme into the gel is slower than the rate of 
enzymatic degradation. Models focusing on the release mechanisms are based on hydrolytic 
degrading polymers. 
CHALLENGES OF HYDROGEL DEVICES 
There are still many challenges associated with the modeling of drug delivery 
phenomena and release profiles related to complex hydrogel systems. Fundamental 
understanding of drug transport processes helps in developing a suitable mathematical model. 
Mass transport governs the translocation of drug from the interior to the surrounding 
environment of hydrogel devices. Factors affecting mass transport of encapsulated molecules 
are as follows. 
 Network cross linking density 
 Extent of swelling 
 Gel degradation 
 Size and charge of the encapsulated molecules 
 Physical interactions between the encapsulated molecules and the polymer matrix 
 Drug – ligand binding present within hydrogel devices. 
APPLICATION OF HYDROGELS 
Wound Healing – Modified polysaccharide found in cartilage is used in formation of 
hydrogels to treat cartilage defects. For example, the hydrogel of gelatin and polyvinyl 
alcohol (PVA) together with blood coagulants are formulated. 
1. Soft Contact Lenses (silicon hydrogels and polyacrylamides) – The first commercially 
available silicon hydrogels adopted two different approaches. First approach by Bausch 
and Lomb was a logical extension of its development of silicon monomers with enhanced 
compatibility in hydrogel forming monomers. The second by Ciba vision was the 
development of siloxy monomers containing hydrophilic polyethylene oxide segments 
and oxygen permeable polysiloxane units. 
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2. Industrial Applicability - Hydrogels are used as absorbents for industrial effluents like 
methylene blue dye. Another example is adsorption of dioxins by hydrogel beads. 
3. Tissue Engineering – Micronized hydrogels are used to deliver macromolecules 
phagosomes) into cytoplasm of antigen-presenting cells. This property is also utilized in 
cartilage repairing. Natural hydrogel materials used for tissue engineering include 
agarose, methylcellulose and other naturally derived products.  
4. Drug Delivery in GI Tract – Hydrogel deliver drugs to specific sites in the GIT. Drugs 
loaded with colon specific hydrogels show tissue specificity and change in the pH or 
enzymatic actions cause liberation of drugs. They are designed to be highly swollen or 
degraded in the presence of micro flora.  
5. Rectal Delivery – Hydrogels showing bio adhesive properties are used for rectal drug 
delivery. Miyazaki et al. explored the xyloglucan gel with a thermal gelling property as 
matrices for drug delivery. 
6. Ocular Delivery – Chitoni et al. reported silicon rubber hydrogel composite ophthalmic 
inserts. Cohen et al. developed in-situ forming gelling system of alginate with high 
gluconic acid contents for the ophthalmic delivery of pilocarpine. 
7. Transdermal Delivery – Swollen hydrogels can be used as controlled release devices in 
the field of wound dressing. Hydrogel based formulations are being explored for 
transdermal iontophoresis to obtainnicotine. 
8. Subcutaneous Delivery – Hydrogel formulations for subcutaneous delivery of anticancer 
drugs are being prepared viz. cross-linked PHEMA was applied to cytarabine (Ara-
c).implantable hydrogels are now leading towards the development of biodegradable 
systems which don‘t require surgical removal once the drug has been administered. 
9. Novel Hydrogel For Controlled Drug Delivery – HYPAN is the novel hydrogel having 
properties useful controlled drug delivery. Physical network of crystalline clusters 
distinguishes HYPAN hydrogels from others. 
10. Hydrogel For Gene Delivery – Modification of hydrogel composition leads to effective 
targeting and delivery of nucleic acids to specific cells for gene therapy. Hydrogel 
versatility has potential application in the treatment of many genetic and/or acquired 
diseases and conditions. 
11. Cosmetology – Hydrogels when implanted into breast accentuate them for aesthetic 
reasons. These implants have silicon elastomer shell and are filled with hydroxyl propyl 
cellulose polysaccharide gel.  
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12. Tropical Drug Delivery – Instead of conventional creams, hydrogel formulation are 
employed to deliver active components like Desonide, a synthetic corticosteroid used as 
an anti – inflammatory for better patient compliance. 
13. Protein Drug Delivery – Interleukins conventionally administered as injection are now 
given as hydrogels which show better compliance and form in-situ polymeric network 
and release proteins slowly. 
SOLID DISPERSION 
Many potential drug candidates are characterized by a low oral bioavailability. Often 
poor drug dissolution / solubility rather than limited permeation through the epithelia of the 
gastrointestinal tract are responsible for low oral bioavailability. Thus aqueous solubility of 
any therapeutically active substance is a key property as it governs dissolution, absorption 
and thus the in-vivo efficacy. Drugs with low aqueous solubility have low dissolution rates 
and hence suffer from oral bioavailability problems3. Various techniques for the 
improvement of the dissolution rates of poorly water soluble drugs include micronization, 
inclusion complexation with cyclodextrins, conversion into amorphous drug and formation of 
solid dispersions with hydrophilic carriers2. Solid dispersion technique is widely used to 
increase the intrinsic solubility and dissolution and in turns oral bioavailability of poorly 
water soluble compounds. Solid dispersion formulation was developed by Chiou and 
Riegelman. Solid dispersion has traditionally been defined as the ―the dispersion of one or 
more active ingredients in an inert excipient or matrix‖ where the active ingredients could 
exist in finely crystalline, solubilized or amorphous states.3
 
 It is the most promising method to formulators because of ease of preparation, ease of 
optimization and reproducibility6. Solid dispersion systems can increase dissolution rate and 
bioavailability of water insoluble drugs. In solid dispersion systems, a drug may exist as an 
amorphous form in inert hydrophilic carriers to form solid solutions. When they are exposed 
to aqueous media, the carriers dissolve, and the drug is released as very fine colloidal 
particles. This greatly reduces particle size and increases surface area, which results in 
improved dissolution rates and per oral absorption. Furthermore, no energy is required to 
break up the crystal lattice of a drug (normally present in a crystalline solid dosage form) 
during the dissolution process. Drug solubility and wettability may be increased by 
surrounding hydrophilic carriers. 
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TYPES OF SOLID DISPERSION: 
1. Binary solid dispersion: It consists of drug and a polymeric carrier. 
2. Ternary solid dispersion: It consists of drug, a polymeric carrier and a surfactant. 
Generally used surfactant is polysorbate 80 which plays an important positive role in 
dissolution of the solid dispersion both the binary and ternary solid dispersions enhanced the 
dissolution of poorly water soluble drugs. Moreover, the dissolution of ternary solid 
dispersion is found faster compared with that of binary solid dispersion 7.This was because of 
polysorbate 80, which improved the wettability and solubilized the non-molecularly 
dispersed or crystalline fraction of drug (ex. Ofloxacin). 
3. Surface solid dispersion: Surface solid dispersion is formulated with polymers such as 
polyvinyl pyrrolidone, polyethylene glycol and polyvinyl pyrrolidone-vinyl acetate 
copolymer by fusion technique to improve its solubility. Preparation of surface solid 
dispersion, a technique that provides deposition of the drug on the surface of certain 
materials, can alter the dissolution characteristics of drug. Deposition of drug on the surface 
of an inert carrier leads to reduction in particle size of drug, therapy providing faster rate of 
dissolution. 
SUITABLE PROPERTIES OF A CARRIER FOR 
SOLID DISPERSIONS 
Following criteria should be considered during selection of carriers:  
 High water solubility – improves wettability and enhances dissolution  
 High glass transition point – improve stability  
 Minimal water uptake (reduces TG) 
 Soluble in common solvent with drug –solvent evaporation  
 Relatively low melting point –melting process  
 Capable of forming a solid solution with the drug-similar solubility parameters 
First generation carriers 
Crystalline carriers: Urea, Sugars, Organic acids. 
Second generation carriers 
Amorphous carriers: Poly ethylene glycol, Povidone, Poly vinyl acetate, Poly 
methacrylate, cellulose derivatives 
Third generation carriers 
Surface active self-emulsifying carriers: Poloxamer 408, Tween 80, Gelucire 44/14. 
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SOLVENT SELECTION FOR SOLID DISPERSION SYSTEMS 
In order to prepare solid dispersion, solvents should be selected on the basis of 
following criteria:  
 Dissolve both drug and carrier. 
 Toxic solvents to be avoided due to the risk of residual levels after preparation                         
e.g. chloroform and dichloromethane  
 Ethanol is a less toxic alternative 
 Water based systems preferable  
 Use of surfactants to create carrier drug solutions but care should be taken as they can 
reduce the glass transition point. 
Class I Solvents (Solvents to be avoided) 
Solvents in Class I should not be employed in the manufacture of drug substances, 
excipients and drug products because of their deleterious environmental effect Table 1. 
Class II Solvents (Solvents to be limited) 
Solvents in Table 2 should be limited in pharmaceutical products because of their 
inherent toxicity. 
Class III Solvents (Solvents with low toxic potential) 
Solvents in class III (shown in table 3) may be regarded as less toxic and of lower 
risk to human health. Class III includes no solvents known as a human health hazard at level 
normally accepted in pharmaceuticals. 
Class IV Solvents (Solvents for which no adequate toxicological data was found) 
Some solvents may also be of interest to manufacturers of excipients, drug substances, 
or drug products for example Petroleum ether, isopropyl ether. However, no adequate 
toxicological data on which to base a PDE was found. 
Table1. List of some Class I Solvents 
Solvent Concentration LIMIT 
(ppm) 
Concern 
Benzene 
Carbon tetrachloride 
 
1,2-dichloroethane 
1,1-dichloroethane 
1,1,1-trichloroethane 
2 
4 
 
5 
8 
1500 
Carcinogen 
Toxic and environmental 
hazards 
Toxic 
Toxic 
Environmental hazards 
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Table2. Class II Solvents in pharmaceutical products 
 
PDE= Permitted Daily Exposure 
 
 
USES OF SOLID DIPERSION: 
 Solid dispersion improves dissolvability in water of poorly water soluble drug in a 
pharmaceutical composition. 
 Drug is formulated with hydrophilic carrier (ex. poly ethylene glycol) as a solid 
dispersion to increase its aqueous solubility and dissolution. Then super disintegrant 
(ex.croscarmellose sodium) is used in tablet formulation to achieve rapid 
disintegration of tablets prepared by wet granulation method. Thus solid dispersion is 
used in preparing rapid disintegration oral tablets. These rapidly disintegrating tablets 
can be used as an alternative to parenteral therapy enabling patient for self-medication 
even without the aid of water. 
Solvent PDE (mg/day) Concentration LIMIT 
(ppm) 
Chlorobenzene 
Chloroform 
Cyclohexane 
1,2-dichloroethane 
Ethylene glycol 
Methanol 
Pyridine 
Toluene 
3.6 
0.6 
13.8 
18.7 
6.2 
30.0 
2.0 
8.9 
360 
60 
380 
1870 
620 
3000 
200 
890 
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 Solid dispersion is used as formulation vehicle to facilitate the preclinical safety and 
early clinical studies on new chemical entities with very low aqueous solubility. A 
compound with extremely low or negligible aqueous solubility may significantly limit 
the dose range or exposure of the drug achievable in the preclinical and clinical 
studies when formulated via traditional means. In these cases, solid dispersion 
formulations may provide a means to rapidly assess the safety and efficacy profile of 
the drug substance that may be otherwise difficult to obtain. 
 In improving immunosuppressive therapy in lung transplant patients, dry powder 
formulation consisting of a solid dispersion (ex. Cyclosporine A) for inhalation is 
prepared. It can avoid many problems ex. 
o With dry powder inhalation the use of local anesthesia and irritating solvents 
can be avoided. 
o The higher deposition efficiency of dry powder inhalation compared with 
nebulization reduces the need for high metered doses. Solid dispersions are 
known for their dissolution rate enhancing properties of poorly soluble drugs 
such as Cyclosporine. 
 
BENEFITS OF SOLID DISPERSION SYSTEM:  
Solid dispersion systems can provide numerous additional benefits to oral drug therapy 
beyond improving bioavailability such as: 
 Solid dispersion formulations were demonstrated to accelerate the onset of action for 
drugs such as Non-steroidal anti-inflammatory drugs where immediacy of action is 
crucial to relieving acute pain and inflammation. 
 For anti-cancer drugs in particular, solid dispersion systems were shown to provide 
bioavailable oral dosage forms which could be substituted for standard injections to 
improve patient comfort and compliance. 
 Solid dispersion systems were also found to reduce food effect on drug absorption, 
thus increasing the convenience of drug therapy as the need for some drugs to be 
taken with food was eliminated. 
 It was also demonstrated that a solid dispersion- based dosage form allowed for 
greater drug loading per dose and improved stability over a soft gelatin capsule 
formulation which thereby improved the convenience of drug therapy by reducing the 
dosing regimen and eliminating the need for refrigerated storage. 
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 Additionally, the improved absorption efficiency demonstrated for solid dispersion 
systems allows for a reduction in the content of active agent per dose, thus decreasing 
the cost associated with these drug therapies. 
 Finally it was demonstrated the solid dispersion systems can be produced utilizing 
functional carriers that offer the added benefit of targeting the release of highly 
soluble forms of poorly water soluble drugs to an optimum site for absorption. 
 These benefits demonstrate the current contributions and future potential of solid 
dispersion systems toward improving drug therapies for a variety of important 
medical condition whose treatment involves poorly water soluble drugs. 
 
METHOD OF PREPARATION: 
1. Solvent evaporation method 
2. Modified solvent evaporation method 
3. Melting method 
4. Melt-solvent method 
5. Kneading method 
6. Co-grinding method 
7. Co-precipitation method 
8. Co-precipitation with supercritical fluid 
9. Spray drying method 
10. Gel entrapment technique 
 
Fig. 4 Methods of preparation of Solid Dispersion 
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1. Solvent evaporation method:  
Drug and carrier both are dissolved in organic solvent. After complete dissolution, the 
solvent is evaporated. The solid mass is ground, sieved and dried. 
Ex. Solid dispersion of Ofloxacin with polyethylene glycol was prepared by solvent e
 vaporation method. 
2. Modified solvent evaporation method:  
Drug is dissolved in organic solvent at its saturation solubility with continued stirring 
for some time. Polymer is suspended in sufficient amount of water (up to wet mass of 
polymer). The drug solution is poured at once into polymer suspension. The entire solvent 
is evaporated. The mass obtained is dried. 
3. Melting method:  
Accurately weighed drug and carrier are mixed using glass mortar and pestle. The 
mixture is heated at or above the melting point of all the components to achieve a 
homogenous dispersion. It is then cooled to obtain a congealed mass. It is pulverized and 
sieved. 
Ex. Albendazole and urea solid dispersion was prepared this method. 
4. Melt-solvent method:  
Accurately weighed drug is dissolved in organic solvent and the solution is 
incorporated into the melt of mannitol by pouring into it. It is suddenly cooled. The mass 
is kept in desiccator for complete drying. The solidified mass is crushed, pulverized and 
passed through sieve. 
5. Kneading method:  
A mixture of accurately weighed drug and carrier is wetted with solvent and kneaded 
thoroughly for some time in a glass mortar. The paste formed is dried and sieved. 
Ex. furosemide and crospovidone solid dispersion was prepared by this method. 
6. Co-Grinding method:  
Accurately weighed pure drug powder and the carrier are physically mixed for some 
time using a blender at a specified speed. The mixture is then charged into the chamber of 
a vibration ball mill. A certain number of steel balls are added. The powder mixture is 
ground. Then the sample is collected and kept at room temperature in a screw capped 
glass vial until use.  
Ex. chlordiazepoxide and mannitol solid dispersion was prepared by this method. 
7. Co-precipitation method (co-evaporates):  
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Accurately weighed carrier is dissolved in water and drug in organic solvent. After 
complete dissolution, the aqueous solution of carrier is then poured into the organic 
solution of the drug. The solvents are then heated and evaporated. The dispersion is 
pulverized with pestle and mortar, sieved and dried. 
8. Co-precipitation with supercritical fluid: 
Conventional methods for the preparation of solid dispersions include either the 
fusion or solvent processes, with supercritical fluid processing (SCP) emerging as an 
alternative solvent- evaporation method for formulating co precipitates of smaller particle 
size, lower residual organic solvent and better flow ability. A supercritical fluid exists as a 
single fluid phase above its critical temperature and pressure. Carbon dioxide is currently 
the most commonly used supercritical fluid because of its low critical temperature of 
carbon dioxide makes it attractive for processing heat labile pharmaceuticals. In the 
context of manufacturability, rate of cooling and solvent removal is stringently controlled, 
resulting in acceptable batch to batch variation. 
A precipitation vessel with a nominal capacity of 50ml was loaded with a 7ml solution of 
pure drug or drug: polymer (carbamazepine: polyethylene glycol) in acetone. The 
supercritical carbon dioxide was added from the bottom of the chamber and when the 
liquid phase expanded, the formed particles were retained in the vessel by a suitable filter. 
During the co-precipitate formation, the pressure was fixed at 70bar and the temperature 
at 40
o
C. 
9. Spray drying method:  
Accurately weighed amount of drug with lipid carrier are dissolved in methanol to 
obtain a clear solution. This solution is then spray dried using a laboratory scale dryer. 
The sample is stored over silica gel in a vacuum desiccator. 
10. Gel entrapment technique: 
Carrier for example hydroxyl propyl methyl cellulose is dissolved in organic solvent 
(dichloromethane) to form a clear and transparent gel. Then drug for example 
carbamazepine is dissolved in gel by sonication for few minutes. Organic solvent is 
evaporated under vacuum. Solid dispersions are reduced in size by glass mortar and 
sieved. 
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THE UNDERLYING PRINCIPLES FOR IMPROVING THE DISSOLUTION 
PROPERTIES OF DRUGS BY SOLID DISPERSION TECHNIQUES ARE: 
 Reducing particle size. 
 Altering the crystalline morphology. 
 Intimately mixing the drug with hydrophilic excipients .By altering the bulk drug 
according to these principles, drug particle surface area is increased, the 
thermodynamic barrier to dissolution imposed by the crystal lattice is eliminated and 
the wetting properties of the drug particles are enhanced. 
 
MECHANISMS SUGGESTED BEING RESPONSIBLE FOR THE IMPROVED 
AQUEOUS SOLUBILITY / DISSOLUTION PROPERTIES OF SOLID 
DISPERSIONS 
INCLUDES: 
 Reduction of the particle size of the incorporated drug: In solid dispersions, the 
particle size of the drugs was reduced, and the wettability and the dispersibility of the 
drugs were enhanced; therefore, drug dissolution was improved markedly. 
 Partial transformation of crystalline drug to the amorphous state. 
 Formation of solid solution. 
 Formation of complexes. 
 Reduction of aggregation and agglomeration. 
 Improved wetting of the drug and solubilization of drug by the carrier at the diffusion 
layer. 
 
EVALUATIONS OF SOLID DISPERSION: 
 It is highly acceptable, that often more than one of these phenomena determine the 
rate and extent of dissolution. Therefore, Bragg-Brentano powder diffractometry, 
differential scanning calorimetry, infrared spectroscopy, solubility and dissolution 
experiments are routinely used to study the relationship between dissolution and 
physicochemical state of solid dispersion. 
 Transformation of crystalline drug or semi crystalline polyethylene glycol to the 
amorphous state and formation of polymorphic drug forms can be detected by Bragg- 
Brentano powder diffractometry. 
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 Differential scanning calorimetry offers the possibility to evaluate the crystallinity of 
both drug and polymer phase and to characterize polymorphic and amorphous phases. 
Differential scanning calorimetry can be used to study solid dispersion to determine 
whether the phase is monotectic or eutectic in nature. A monotectic system is one 
where little or no interaction occurs whereas a eutectic system is one where little or no 
interaction occurs. 
 Infrared spectroscopy reveals crystallographic changes of drug and polymer 
molecules, such as hydrogen bonds which are indicative of complex formation. 
 Equilibrium solubilities of the drug in aqueous polymer solutions of different polymer 
concentrations reveal the solubilization capacity of the polymer for the drug. 
 Micro –Raman spectroscopy with X- Ray Diffraction is used for characterization of 
the distribution, polymorphism and stability of drug in its solid dispersion in 
polyethylene glycol. 
 
MARKETED PRODUCTS:  
Commercial products based on solid solution /dispersion is: 
 Gris-PEG, a griseofulvin- PEG fusion method solid dispersion, was manufactured 
initially by Dorsey / Sandoz and reached the market in the mid- 1970s.Gris-PEG was 
developed as tablet product, and this led to two USP monographs for griseofulvin 
tablets. The solid dispersion form is referred to as ultra-micro size griseofulvin tablets 
USP and offers improved bioavailability and two- thirds reduced dosage compared to 
griseofulvin tablets USP. The griseofulvin tablets USP are manufactured from 
micronized drug substance using a conventional tableting approach. Griseofulvin 
solid dispersion tablets are currently marketed by a number of manufacturers and 
contain corn starch, lactose, magnesium stearate, PEG, and sodium lauryl sulfate as 
inactive ingredients. 
 Cesamet, a nabilone-PVP solvent method solid dispersion manufactured by Eli Lilly 
and Co. has been marketed internationally since 1982. Eli Lilly discontinued 
marketing Cesamet contain PVP and corn starch as inactive ingredients and is 
presented as a capsule product. 
 Solid dispersion formulation of Troglitazone (Rezulin) is marketed by Parke-Davis25. 
 Solid solutions of lopinavir and ritonavir in poly vinyl pyrrolidone-vinyl acetate 
copolymer successfully enabled a reformulation of "Kaletra" (Abbott Laboratories, 
Abbott Park, IL). In addition to reducing the dosage burden from six soft gel capsules 
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to four tablets, tablets made with the solid solutions eliminate the need for 
refrigeration. 
 "Sporanox" (Janssen Pharmaceutical, Titusville, NJ) is a solid dispersion of 
itraconazole in hypromellose that has been layered onto sugar spheres. 
 The most recently approved product is the non-nucleoside reverse transcriptase 
inhibitor "Intelence" (Tibotec, Yardley, PA) an amorphous, spray-dried solid 
dispersion of etravirine, hypromellose, and microcrystalline cellulose. 
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LITERATURE REVIEW 
 
U. D. SHIVHARE et al.,
[9]
developed and evaluated diclofenac sodium gel using water 
soluble polyacrylamide polymerHigh molecular weights water soluble homopolymer of 
acrylamide are reported to possess very high viscosity in low concentration, transparency, 
film forming properties and are useful in formation of gel. The diclofenac sodium gels were 
prepared by using different concentration of polyacrylamide for topical drug delivery with an 
objective to increase transparency and spread ability. These preparations were further 
compared with marketedDiclofenac sodium gel. Spreadability and consistency of 
polyacrylamide gel containing diclofenac sodium (F9) were 6.5g.cm/sec and 5mm as 
compared to 5.5g.cm/sec and 10mmrespectively of marketed gel, indicating good 
spreadability and consistency of the preparedgel (F9). The transparency of prepared batch F9 
was good as compared to the marketed gel. The percent drug release was 97.11 and 98.66 
from F9 and marketed gel respectively. No irritation was observed by skin irritation test. 
Stability studies under accelerated condition showed satisfactory results. It can be concluded 
that polyacrylamide gel containing diclofenac sodium showed good consistency, 
homogeneity, spreadability and stability and has wider prospect for topical preparations. 
M.a.saleemet al.,
[10]
jul-sep.2010formulated and evaluated of meloxicam solid dispersion 
incorporated topical gels,Solid dispersion complexes of meloxicam were prepared by using 
cyclodextrins (BCD, HPBCD), PVP and urea by kneading method in different molar and 
weight ratios. The complexes werecharacterized by DSC and IR, suggested that no chemical 
interaction between drug and carrier. The solubility,dissolution and permeability of 
complexes were markedly increased as compared to pure drug. Solidcomplexes were 
incorporated in 1% carbopol to prepare gels and evaluated for pH, drug content,viscosity, 
invitro permeability through rat skin. Invitro permeation study reveals that the flux (Jss)and 
enhancement factor increases with increase in concentration of BCD, HPBCD and 
decreaseddramatically in case of HPBCD with ratio of 1:2. Similar changes in pattern of 
permeation wereobserved with urea and PVP complexes .Hence it can be concluded that solid 
dispersion complexincorporated gel shows highest permeation as compared to plain drug 
gels. 
P.K. LAKSHMI et al.,
[11]
2011 this study aimed to increase the therapeutic effectiveness of 
ibuprofen by increasing its transdermal permeation, via solid dispersion incorporated in gel. 
2- Hydroxy propyl beta cyclodextrins (2-HPβ-CD) and β-cyclodextrin (β-CD) were used as 
carriers and carbopol 941 was the gelling agent. Eight solid dispersion formulations of 
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ibuprofen were prepared using different drug: polymer ratios viz. 1:0.5, 1:1, 1:2, and 1:3 for 
2-HPβ-CD and β cyclodextrin using the co-evaporation method, and were evaluated for 
partition coefficient, dissolution studies, and Fourier Transform Infra-Red (FTIR) 
spectrophotometer. The optimized solid dispersion of ibuprofen was incorporated into gel and 
was compared with penetration enhancers. The formulations were analyzed to determine their 
pH, spreadability, viscosity, and in vitro drug release. The absence of extraneous interactions 
among ingredients was confirmed by FTIR, and differential scanning calorimetry (DSC). The 
formulation with 1:0.5 SDIB (drug: HPβCD) with a partition coefficient of 1.28 was 
incorporated in carbopol gel, and produced 98.21% drug release compared to solid dispersion 
of ibuprofen with menthol (SDIBM5%), which produced 96.5% drug release. In ex vivo 
studies, SDIB and SDIBM5% formulations gave 94.3% and 92.36% drug release within 24h. 
The percent inhibitions of the edema formation by the gels were in the range of 18.32% to 
67.96%, and the maximum inhibition was shown by the SDIB formulation. Therefore, SDIB 
formulation incorporated in gel produced better results than other formulations prepared with 
permeation enhancers. Stability studies conducted for SDIB incorporated gel according to 
International Conference on Harmonization guidelines showed it to be stable for two months.  
Swami N.G.N et al.,
[12]
Formulated and evaluated diclofenac sodium gels using sodium 
carboxymethyl hydroxypropyl guar and hydroxypropyl methylcellulosein this investigation, 
Diclofenac sodium gels were formulated employing Sodium carboxymethyl hydroxy propyl 
guar and Hydroxypropyl methylcellulose as gelling agents. Hydroxypropyl methylcellulose 
(K4M) was employed at 5 %w/w strength whereas, Sodium carboxymethyl hydroxypropyl 
guar formed a gel at 2.5 % w/w strength, gels were subjected for various evaluation tests such 
as pH measurement, assay, stability study, rheological evaluation, and invitro release studies 
across hairless albino rat skin. Gels formulated using Sodium carboxymethyl hydroxypropyl 
guar displayed a pH value of 7.48, whereas hydroxypropyl methylcellulose gels revealed a 
pH value of 7.26. Stability  studies revealed good physical stability and assay values did not 
show much variation from the initial drug content in0 0 both the cases with formulations 
stored at 25 C, 60% RH and 40 C, 70% RH for six months. Hydroxypropyl methylcellulose 
at 5% w/w strength revealed shear-thinning property, whereas Sodium carboxymethyl 
hydroxypropyl guar at 2.5 % w/w strength revealed both pseudo plastic and thixotropic 
property. The rheological data were fitted into Martin and Co’-worker equation to obtain a 
linear relationship and from the linear curve fittings, the 'N'- values; the possible flow indices 
for pseudo plasticity were arrived at. A 'N' value of 4.65 was obtained for Sodium 
carboxymethyl hydroxypropyl guar gels in contrast to a 'N' value of 1.52 in case of 
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Hydroxypropyl methylcellulose gels. When subjected to In-vitro release studies across 
hairless albino rat skin, Sodium carboxymethyl hydroxypropyl guar based gels revealed a % 
cumulative drug release of 25.66 in contrast to a % cumulative drug release of 20.80 in case 
of Hydroxypropyl methylcellulose based gels at the end of 6 hours. From the above 
observations, Sodium carboxymethyl hydroxypropyl guar seems to be a promising 
pharmaceutical adjuvant in the formulation of Diclofenac sodium gel. 
MALAYK.DAS et al.,
[13]
The potential gastrointestinal disorders associated with oral 
administration of rofecoxib can be avoidedby delivering the drug to the inflammation site at a 
sustained, concentrated level over an extended period oftime. Hydroxypropyl methylcellulose 
(HPMC), sodium alginate and Carbopol 940 were used in an attempt todevelop topical gel 
formulations of rofecoxib. The effects ofpolymer composition on the rate of drug releasefrom 
the gel formulations were examinedthrough cellulose membrane mounting on a Keshary-
Chien diffusioncell. The effects of initial drug concentration and viscosity on the permeation 
rate of rofecoxib from the gel formulationswere evaluated using rat epidermis at 37 +0.5ºC. 
The anti-inflammatory activity of the rofecoxib gelformulation was evaluated using the rat 
hind paw edema model. The gel formulation consisting of 4% w/w sodiumalginate-Carbopol 
940 at 3:1 ratio was found to be suitable for topical application based on in vitro 
evaluationand ex vivo permeation studies. The drug permeation rate increased with an 
increase of the initial drug concentrationin gels up to 25 % w/w. An inverse relationship was 
observed between the in vitro drug release rate/exvivo permeation rate and viscosity of the gel 
formulations. The anti-inflammatory activity of 4% w/w sodiumalginate-Carbopol 940 gel 
containing 25% w/w rofecoxib in the rat hind paw edema model reveals that the drugwas 
delivered to the inflammation site at a controlled level over a period of 6 h. These results 
suggest the feasibilityof the topical gel formulation of rofecoxib. 
Azmail Khan et al.,
[14]
The present study was investigated the Aceclofenac solid dispersions 
gel of various compositions were formulated and among these F1; Aceclofenac solid 
dispersion incorporated gel of HPMC (Hydroxy propyl methyl cellulose) and F2; 
Aceclofenac solid dispersion incorporated gel of Carbopol 940 subjected for transdermal in 
vivo efficacy study on rats through abdominal skin. The F1 and F2 were compared with that 
of control. The F1 found significant increase (P <0.05) in percent inhibition value at 4 h and 
(P <0.01) at 8 h whereas F2 results obtained significant increase (P <0.05) in 
percentinhibition value at 8 hours and (P <0.01) at 12 h when compared with control after 1 
hour on carrageenan-induced paw edema in rats. The results suggested that solid dispersion 
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incorporated gels of HPMC are improved transdermal delivery for Aceclofenac than the solid 
dispersion incorporated gels of Carbopol 940. 
 Lalit Kumar et al.,
[15]
Nimesulide is a second generation non–steroidal anti–inflammatory 
agent, which is widely usedin the long term therapy of rheumatoid arthritis, in alleviating 
pain and inflammation. But its short half-life (only 3–4hrs.), so its causes more fluctuation. 
After oral administrationNimesulide causes to produces heart burn, nausea, loose motions, 
pruritus, etc. The present studybased on the preparation of bioadhesive topical gel of 
Nimesulide, so as to avoid all gastric sideEffects. For the preparation of bioadhesive topical 
gel natural polymer angel marmelos (plantBale) was used. Bioadhesive polymers are the 
agents which increases the contact between theFormulation and biological membrane, so as 
to avoid the fluctuation of formulation and behave as a sustained release formulation. In the 
present study, prepared bioadhesive topical gel was evaluated with the help of different 
parameters like drug content, spreadability, extrudability, swelling index study, in–vitro drug 
diffusion study, in-vitro drug release kinetic study and ex–Vivobio adhesive measurement. On 
the basis of in–vitro drug diffusion study and ex–vivoBioadhesive measurement property of 
gel, we have concluded that natural polymer aegelMarmelosis the best polymer for the 
preparation of sustained release bioadhesive topical gel. 
V.B.Yadav et al.,
[16]
Indomethacin (IM) is one of the most widely used non-steroidal anti-
inflammatory active pharmaceutical agents. However, it’s limited aqueous solubility and poor 
flow ability creates bioavailability and formulation related problems. Role of various water-
soluble carriers was studied for dissolution enhancement of a poorly soluble model drug, 
Indomethacin, using solid dispersion approach. Solid dispersions of Indomethacin with 
lactose monohydrate and different polymers Polyethylene glycol- 6000(PEG), Hydroxy 
Propyl Methyl Cellulose (HPMC), PolyvinylPyrrolidine (Povidone-30), and Beta 
Cyclodextrin (BCD) were prepared by kneading method. In the present investigation by 
keeping the constant amount of lactose monohydrate the effect of different hydrophilic 
polymers on solubility and dissolution were studied. The prepared solid dispersions were 
evaluated for content, saturation solubility, and dissolution and flow ability parameters. 
Powdered solid dispersion with lactose monohydrate and used hydrophilic polymers showed 
approximately 10-20 fold increases in solubility over the pure drug. The all prepared solid 
dispersions shows improvement in dissolution profile and flow ability compared to the raw 
indomethacin. Thus, the bioavailability of this poorly water-soluble drug and their flow 
ability was greatly enhanced by formulation as solid dispersions with different hydrophilic 
polymers. 
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Naresh G et al.,.
[17]
 The aim of this study was to prepare and evaluate gels incorporating solid lipid 
nanoparticles (SLNs) of diclofenac sodium for systemic delivery of the active after topical 
application. SLNs were prepared using hot homogenization followed by sonication technique and 
these were incorporated into freshly prepared carbopol gel. Three different gel formulations (DSL1, 
DSL2 and DSL3) were prepared and characterized for particle size, charge, viscosity, morphology, 
and drug-lipid compatibility. The gels were evaluated for in vitro drug release, ex vivo permeation 
studies and in vivo absorption. The gels enriched with SLN sustained the drug release for 24 h both in 
vitro and in vivo. The results suggest enhancement in systemic delivery of diclofenac sodium with 
gels incorporating SLNs. 
Bazigha K Abdul Rasool et al.,.
[18]
Ibuprofen gel formulations, incorporating various 
permeation enhancers, were prepared usingChitosan as a gelling agent. The formulations 
were examined for their in vitro characteristics includingviscosity, pH and drug release as 
well as in vivo pharmacological activities. Carrageenan-induced ratpaw edema model was 
used for the evaluation of their analgesic and anti-inflammatory activities. Acommercial 
ibuprofen gel product (Ibutop®) was used as a reference.The formulations containing 5 % of 
either menthol or glycerol as permeation enhancers gavedrug release patterns comparable to 
that of the reference product. Propanol increased the apparentviscosity of the test gels to the 
same extent as that of the reference. Drug release from the formulationsfitted best to the 
Higuchi model. A significant in vivo analgesic effect was produced by the testformulations 
containing 5 % menthol and 20 % propylene glycol and the effect was superior to 
thatobtained with the reference product. However, no significant anti-inflammatory activity 
was exerted byany of the test gel formulations (p > 0.05).Ibuprofen gel preparations 
containing 5 % menthol and 20 % propylene glycol, respectively, exhibited pronounced 
analgesic activity and could be further developed for topical andsystemic delivery of 
ibuprofen 
Sanju Dhawan et al.,
[19]
The treatment for chronic anal fissure (CAF) has undergone a 
transformation inrecent years from surgical to medical. Both the approaches share the 
commongoal of reducing the spasm of anal sphincter. Though surgical treatment has ahigh 
success rate but it can permanently impair fecal continence in largenumber of patients. 
Smooth muscle relaxation seems to be a novel way bywhich more than 60% of the patients 
can be cured with the topical use of theagents. In the present investigation, diltiazem 
hydrochloride gels were preparedusing FDA recommended polymers [hydroxypropylmethyl 
cellulose (HPMC),methylcellulose (MC) and polyethylene oxide (PEO grade 301 and 303)] 
fortopical application in CAF. Increasing the concentration of the polymersignificantly 
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increased the consistency of the gels. All the formulations exhibited pseudoplastic flows with 
no thixotropic. The values of flow index (n) were found tobe less than one for all the gels 
confirming the shear thinning behavior of allthe gels. HPMC and MC gels were found to be 
stable at accelerated stabilityconditions while the bio adhesion of PEO gels was highest. Even 
after exposureto heat and humidity, no significant change was observed in the 
contentuniformity, pH, clarity, texture profile analysis and rheological properties of 
theHPMC and MC gels. The rheograms and various power law equationparameters of these 
gels were found comparable at various time points in theaccelerated stability study. However, 
PEO gels failed in accelerated stability studies at one month sample. When four selected gel 
formulations (HPMCL4,MCL3, P1BL3 and P3BL3.5) were applied topically by six patients 
each, Gastrointestinal Quality of Life Index (GIQLI) score of each patient wasimproved at 
the end of 8 weeks. No adverse effects were reported by any of thepatients. Hence 2% DTZ 
gel was found to be effective in the treatment of analfissures. 
M Najmuddin et al.,
[20]
The Goal of the present investigation was to design and evaluate gels 
for topical delivery of water insoluble antifungal agent Ketoconazole with an aim to increase 
its penetration through skin and thereby its flux. Ketoconazole is a broad spectrum imidazole 
derivative useful in the treatment of superficial and systemic fungalinfections. The solubility 
of Ketoconazole is increased by complications with ß-cyclodextrin were prepared bysolvent 
evaporation technique with 1:1 and then incorporated into gels. The complex was 
characterized byinfrared spectroscopy. There was no interaction between drug and carrier. 
Gels have gained more and moreimportance because the gel-bases formulations are better 
percutaneous absorbed than creams and ointmentbases. Therefore, Ketoconazole gel 
formulations were made with different polymers like carbopol 940, hydroxyl propyl methyl 
cellulose, methyl cellulose, and sodium carboxymethylcellulose, containing various 
permeationenhancers namely sodium lauryl sulphate (0.5-1.0%) and dimethyl sulfoxide (5-
20%) in different proportions. Theformulated gels were evaluated for various 
physicochemical parameters like, drug content, pH, viscosity, spreadability, extrudability, in-
vitro drug release. The in-vitro drug release study were carried out using pH 7.4phosphate 
buffer, All the formulated topical preparations showed pH in the range of 6.5 to 7.4, and also 
showedgood spreadability, extrudability. The carbopol 940 with 15% of dimethyl sulfoxide 
(KCD3) showed best in-vitrodrug release 98.07% at the end of 6 hrs. 
B.Radha Madhavi et al.,
[21]
Zafirlukast is an oral leukotriene receptor antagonist used in the 
treatment of asthma. Poor solubility in biological fluids is the major problem with this drug 
which results in poor bioavailability after an oral administration. The rate of absorption and 
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the extent of bioavailability for such a poor soluble drugs were controlled by rate of 
dissolution in gastrointestinal fluids. Hence an attempt has been made to enhance the 
solubility of the drug by preparing its complex with β-cyclodextrin. FT-IR studies were 
performed. Drug complexing agent interactions were investigated using differential scanning 
calorimetry (DSC). The study clearly shows that the dissolution rate of zafirlukast may be 
enhanced to a great extent by solid dispersion technique using kneading method. This is due 
to the reason that the cyclodextrins increased the aqueous solubility of poorly soluble drug by 
forming inclusion complexes with heir a polar molecules and functional groups. 
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DRUG PROFILE 
[5, 6, 7] 
Diclofenac Sodium: 
 
Molecular Formula: C14H11C12NO2 
Molecular Weight: 318.10 
Chemical Name: 2-[(2, 6-dichlorophenyl) amino] benzene acetic acid, mono potassium salt 
Solubility: Freely soluble in methanol; soluble in ethanol (95 per cent); sparingly soluble in 
water and in glacial acetic acid; practically insoluble in ether, in chloroform and in toluene. 
Indications: 
 Orally for symptomatic treatment of osteoarthritis, ankylosing spondylitis, primary 
dysmenorrhea, acute gouty arthritis and for relief of pain, including postoperative (e.g., 
orthopedic, gynecologic, oral) pain, in adults. 
 In combination with misoprostol for the symptomatic treatment of osteoarthritis and 
rheumatoid arthritis in patients at high risk for developing NSAIDS-induced gastric or 
duodenal ulcers and in patients at high risk for developing complications from these ulcers. 
 Topically (as gel) for the symptomatic treatment of osteoarthritis related joint pain. Used for 
joints amenable to topical therapy (e.g., hands, knees), has not been evaluated on joints of the 
spine, hip, or shoulders. 
 Orally or topically for symptomatic treatment of infusion-related superficial thrombophlebitis. 
Dosage and Administration: 
Oral Administration 
 Diclofenac sodium delayed-release (enteric-coated) and extended-release tablets are not 
recommended for relief of acute pain or primary dysmenorrhea1 because of slow onset of action. 
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Topical Administration 
Diclofenac Sodium 1% Gel 
 Apply gel 4 times daily to the affected joint. Use the dosing card from the manufacturer to 
measure the appropriate dose.  Apply the gel within the oblong area of the dosing card up to the 
appropriate (2- or 4-g of gel) line; then use the dosing card to apply the gel. Gently massage the 
gel into the skin; ensure gel is applied to the entire affected joint (e.g., foot [including sole, top of 
foot, and toes], knee, ankle, hand [including palm, back of hand, and fingers], elbow, and wrist). 
Diclofenac Epolamine Transdermal System 
 Apply transdermal system to the most painful area twice daily.  Apply to intact skin; do not 
apply to damaged skin (e.g., wounds, burns, infected areas of skin, areas affected with eczema or 
exudative dermatitis). 
Dosage: Oral 
May change dosage to 50 or 75 mg twice daily in patients who do not tolerate usual dosage; 
however, these dosages may be less effective in preventing NSAIA-induced ulcers. 
S.No Preparation Dosage 
1 Diclofenac potassium conventional 
tablets 
100–150 mg daily, given as 50 mg 2 or 3 times 
daily 
2 Diclofenac sodium delayed-release 
tablets 
100–150 mg daily, given as 50 mg 2 or 3 times 
daily or 75 mg twice daily 
3 Diclofenac sodium extended-release 
tablets 
100 mg once daily 
4 Diclofenac sodium (in fixed 
combination with misoprostol) 
50 mg 3 times daily 
 
Topical (gel) 
For lower extremity (i.e., knees, ankles, feet) joint pain, massage 4 g of diclofenac sodium 1% 
gel into the affected joint 4 times daily. 
For upper extremity (i.e., elbows, wrists, hands) joint pain, massage 2 g of diclofenac sodium 1% 
gel into the affected joint 4 times daily. 
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If multiple joints are treated, total daily dose applied to all joints should be ≤32 g of gel daily.  
Rheumatoid Arthritis 
Oral 
May change dosage to 50 or 75 mg twice daily in patients who do not tolerate usual dosage; 
however, these dosages may be less effective in preventing NSAIA-induced ulcers.  
S.No Preparation Dosage 
1 Diclofenac potassium conventional 
tablets 
150–200 mg daily, given as 50 mg 3 or 4 times 
daily 
2 Diclofenac sodium delayed-release 
tablets 
150–200 mg daily, given as 50 mg 3 or 4 times 
daily or 75 mg twice daily 
3 Diclofenac sodium extended-release 
tablets 
100 mg once daily; may increase to 100 mg 
twice daily 
4 Diclofenac sodium (in fixed 
combination with misoprostol) 
50 mg 3 or 4 times daily 
 
Warnings/Precautions 
Consider potential benefits and risks of diclofenac therapy as well as alternative therapies before 
initiating therapy with the drug.  
Cardiovascular Effects 
Selective COX-2 inhibitors have been associated with increased risk of cardiovascular events 
(e.g., MI, stroke) in certain situations. Several prototypical NSAIAs also have been associated 
with increased risk of cardiovascular events.  Current evidence suggests that use of diclofenac is 
associated with increased cardiovascular risk. 
GI Effects 
Serious GI toxicity (e.g., bleeding, ulceration, perforation) can occur with or without warning 
symptoms; increased risk in those with a history of GI bleeding or ulceration, geriatric patients, 
smokers, those with alcohol dependence, and those in poor general health.  
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Renal Effects 
Direct renal injury, including renal papillary necrosis, reported in patients receiving long-term 
NSAIA therapy. 
Hypersensitivity Reactions 
a) Anaphylactic reactions (e.g., anaphylaxis, angioedema) reported. 
b) Immediate medical intervention and discontinuance for anaphylaxis.  
c) Avoid in patients with aspirin triad (aspirin sensitivity, asthma, nasal polyps); caution in 
patients with asthma.  
Dermatologic Reactions 
Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal 
necrolysis) reported; can occur without warning. Discontinue at first appearance of rash or any 
other sign of hypersensitivity (e.g., blisters, fever, and pruritus).  
General Precautions 
Do not use multiple diclofenac-containing preparations concomitantly. Concomitant use of 
diclofenac sodium 1% gel and oral NSAIAs may increase risk of adverse effects.  
Observe the usual cautions, precautions, and contraindications associated with misoprostol 
therapy when diclofenac is used in fixed combination with misoprostol. 
 Hepatic Effects 
Severe, sometimes fatal, reactions including jaundice, fulminant hepatitis, liver necrosis, and 
hepatic failure reported rarely with diclofenac. 
Other Precautions 
Not a substitute for corticosteroid therapy; not effective in the management of adrenal 
insufficiency. 
Obtain CBC and chemistry profile periodically during long-term use. 
Specific Populations 
Pregnancy 
Category C. Avoid use in third trimester because of possible premature closure of the ductus 
arteriosus.  
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Category X (in fixed combination with misoprostol).284 Misoprostol exhibits abortifacient 
activity and can cause serious fetal harm. 
Lactation 
Distributed into milk; 3 discontinue nursing or the drug.  
Pediatric Use 
Safety and efficacy not established in children. 
Good results with oral diclofenac obtained in a limited number of children 3–16 years of age for 
the management of juvenile rheumatoid arthritis. 
Geriatric Use 
Oral diclofenac: Caution advised. Fatal adverse GI effects reported more frequently in geriatric 
patients than younger adults.  
Other Precautions 
Not a substitute for corticosteroid therapy; not effective in the management of adrenal 
insufficiency. It may mask certain signs of infection.  
Obtain CBC and chemistry profile periodically during long-term use. Specific Populations 
Interactions for Diclofenac Sodium 
Protein-bound Drugs 
Only minimally displaces other highly protein-bound drugs from binding sites; however, may be 
displaced from binding sites by other highly protein-bound drugs.51 52 59 61 
Specific Drugs 
S.No Drug Interaction Comments 
1 ACE inhibitors Reduced BP response to ACE inhibitor. 
Possible deterioration of renal function 
in individuals with renal impairment. 
Monitor BP. 
2 Angiotensin II 
receptor antagonists 
Reduced BP response to angiotensin II 
receptor antagonist. 
Possible deterioration of renal function 
in individuals with renal impairment. 
 
3 Antacids Delayed diclofenac absorption.  
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(magnesium- or 
aluminum-
containing) 
4 Anticoagulants 
(warfarin) 
Possible bleeding complications. Caution advised. 
5 Aspirin Decreased peak plasma concentration 
and AUC of diclofenac; limited data 
indicate that diclofenac does not inhibit 
antiplatelet effect of aspirin. 
Increased risk of GI ulceration and 
other complications.  
No consistent evidence that low-dose 
aspirin mitigates the increased risk of 
serious cardiovascular events 
associated with NSAIDS. 
Manufacturer states that 
concomitant use not 
recommended. 
6 Cyclosporine Possible increase in nephrotoxic effects 
of cyclosporine. 
Caution advised. 
7 Diuretics 
(furosemide, 
thiazides) 
Reduced natriuretic effects. Monitor for diuretic 
efficacy and renal 
failure. 
8 Lithium Increased plasma lithium 
concentrations. 
Monitor for lithium 
toxicity. 
9 Methotrexate Severe, sometimes fatal toxicity 
associated with increased plasma 
methotrexate concentrations. 
Caution advised. 
10 Quinolones 
(ciprofloxacin) 
Possible increased risk of seizures.  
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Pharmacokinetics 
Absorption 
Bioavailability 
Well absorbed following oral administration. It undergoes first-pass metabolism; only 50–60% 
of a dose reaches systemic circulation as unchanged drug.  
Peak plasma concentration usually attained within about 1 hour (diclofenac potassium 
conventional tablets), 2 hours (diclofenac sodium delayed-release tablets), or 5.25 hours 
(diclofenac sodium extended-release tablets). Absorbed into systemic circulation following 
topical administration as gel or transdermal system; plasma concentrations generally very low 
compared with oral administration. Following application of a single diclofenac epolamine 
transdermal system to intact skin on the upper arm, peak plasma concentrations occur in 10–20 
hours.  
Following topical application of diclofenac sodium 1% gel, peak plasma concentrations occur in 
about 10–14 hours.  
Moderate exercise does not alter systemic absorption of topically applied diclofenac (transdermal 
system or 1% gel).  
Application of a heat patch for 15 minutes before application of the 1% gel did not affect 
systemic absorption. Not established whether application of heat following gel application 
affects systemic absorption.  
Onset 
Single 50- or 100-mg doses of diclofenac potassium provide pain relief within 30 minutes.  
Duration 
Pain relief lasts up to 8 hours following administration of single 50- or 100-mg doses of 
diclofenac potassium.  
Food 
The food delays the time to reach peak plasma concentration but does not affect extent of 
absorption following administration as conventional, delayed-release, or extended-release 
tablets.1 302 303 
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Distribution 
Extent widely distributed in animals.  
Following oral administration, concentrations in synovial fluid may exceed those in plasma. 
Plasma Protsein Binding >99%. 
Elimination 
Metabolism 
It metabolized in the liver via hydroxylation and conjugation. Some metabolites may exhibit 
anti-inflammatory activity.  
Elimination Route 
It excreted in urine (65%) and in feces via biliary elimination (35%) as metabolites. 
Half-life 
Oral preparations: 1–2 hours.  
Diclofenac epolamine transdermal system: Approximately 12 hours. 
Special Populations 
In geriatric patients, the pharmacokinetic profile similar to that of younger adults.  
In patients with renal impairment, plasma clearance not substantially 
altered,1, 3, 208, 302, 303 although clearance of metabolites may be decreased.  
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POLYMER PROFILE 
[8] 
β – CYCLODEXTRIN 
1. Nonproprietary Names: 
BP: Betadex 
PhEur: Betadexum 
USPNF: Betadex 
2. Synonyms 
β-cycloamylose; β-dextrin; Cavamax W7 Pharma; cycloheptaamylose; cycloheptaglucan; 
cyclomaltoheptose;Kleptose. 
3. Chemical Name and CAS Registry Number 
β-Cyclodextrin [7585-39-9] 
4. Empirical Formula and Molecular Weight 
C42H70O35 - 1135 
5. Structural formula  
 
6. Functional Category 
Solubilizing agent; stabilizing agent. 
7. Description 
Cyclodextrins are cyclic oligosaccharides containing at least six D-(β)-glucopyranose units 
attached by a (14) glycoside bonds. The three natural cyclodextrins, a, b, and g, differ in their 
ring size and solubility. They contain 6, 7, or 8 glucose units, respectively. 
Cyclodextrins occur as white, practically odorless, fine crystalline powders, having a slightly 
sweet taste. Some cyclodextrin derivatives occur as amorphous powders. 
8. Typical Properties 
Compressibility: 21.0–44.0% for b-cyclodextrin 
Density (bulk):0.523 g/cm
3 
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Density (tapped):0.754 g/cm
3 
Melting point:  255–2658C 
Moisture content: b-cyclodextrin: 13.0–15.0% w/w; 
Particle size distribution: 7.0–45.0 mm 
Solubility: b-cyclodextrin: soluble 1 in 200 parts of propylene glycol, 1 in 50 of water at 
20
0
 C, 1 in 20 at 508C; practically insoluble in acetone, ethanol (95%), and methylene 
chloride. g-cyclodextrin: soluble 1 in 4.4 parts of water at 20
0
C, 1 in 2 at 45
0
C. 
Specific rotation [a] D25 +162.0 
Surface tension (at 258C):71mN/m (71 dynes/cm) 
9. Stability and Storage Conditions 
β -Cyclodextrin and other cyclodextrins are stable in the solid state if protected from high 
humidity. 
Cyclodextrins should be stored in a tightly sealed container, in a cool, dry place. 
10. Applications in Pharmaceutical Formulation or Technology 
Cyclodextrin are ‘bucket like’ or ‘cone like’ toroid molecules, with a rigid structure and a 
central cavity, the size of which varies according to the cyclodextrin type. The internal 
surface of the cavity is hydrophobic and the outside of the torus is hydrophilic; this is due to 
the arrangement of hydroxyl groups within the molecule. This arrangement permits the 
cyclodextrin to accommodate a guest molecule within the cavity, forming an inclusion 
complex. 
Cyclodextrins may be used to form inclusion complexes with a variety of drug molecules, 
resulting primarily in improvements to dissolution and bioavailability owing to enhanced 
solubility and improved chemical and physical Stability. 
Cyclodextrin inclusion complexes have also been used to mask the unpleasant taste of active 
materials and to convert a liquid substance into a solid material. 
Β-Cyclodextrin is considered to be nontoxic when administered orally, and is primarily used 
in tablet and capsule formulations. 
In parenteral formulations, cyclodextrins have been used to produce stable and soluble 
preparations of drugs that would otherwise have been formulated using a non-aqueous 
solvent. 
In eye drop formulations, cyclodextrins form water-soluble complexes with lipophilic drugs 
such as   corticosteroids. They have been shown to increase the water solubility of the drug; 
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to enhance drug absorption into the eye; to improve aqueous stability; and to reduce local 
irritation. 
Cyclodextrins have also been used in the formulation of solutions, (9, 10) suppositories, and 
cosmetics. 
11. Safety 
When administered parenteral, β-cyclodextrin is not metabolized but accumulates in the 
kidneys as insoluble cholesterol complexes, resulting in severe nephrotoxicity. 
Cyclodextrin administered orally is metabolized by micro flora in the colon, forming the 
metabolites maltodextrin, maltose, and glucose; which are themselves further metabolized 
before being finally excreted as carbon dioxide and water. 
POLYVINYLPYRROLIDONE 
PVP is soluble in water and other polar solvents. When dry it is a 
light flaky powder, which readily absorbs up to 40% of its weight in 
atmospheric water. In solution, it has excellent wetting properties 
and readily forms films. This makes it good as a coating or an 
additive to coatings. PVP is a branched polymer, that is it structure is 
more complicated than linear polymer but it too is in a two-
dimensional plane. The structure of a polymer greatly depends on its 
integrity and strength, formed through cross-links and bonds. Firstly, 
composition of polymers takes place through polymerization of 
mers, many simple molecules that are repeating structural units called monomers. A single 
polymer molecule may consist of hundreds to a million monomers and may have a linear, 
branched, or network structure. Covalent bonds hold the atoms in the polymer molecules 
together and secondary bonds then hold groups of polymer chains together to form the 
polymeric material. Copolymers are polymers composed of two or more different types of 
monomers. 
Molecular formula (C6H9NO)n 
Molar mass 2.500 - 2.5000.000 g·mol
− 
Appearance white to light yellow, hygroscopic, amorphous powder 
Density 1.2 g/cm³  
Melting point 150 - 180 °C (glass temperature) 
Technical 
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PVP is also used in many technical applications: 
 as an adhesive in glue stick and hot-melt adhesives 
 as a special additive for batteries, ceramics, fiberglass, inks, inkjet paper and in the 
chemical mechanical planarization process 
 as an emulsifier and disintegrant for solution polymerization 
 as a photoresist for cathode ray tubes (CRT) 
 used in aqueous metal quenching 
 for production of membranes, such as dialysis and water purification filters 
 as a binder and complexation agent in agro applications such as crop protection, seed 
treatment and coating 
 as a thickening agent in tooth whitening gels
[7]
 
 as an aid for increasing the solubility of drugs in liquid and semi-liquid dosage forms 
(syrups, soft gelatin capsules) and as an inhibitor of recrystallization 
 as an additive to Doro's RNA extraction buffer 
 as a liquid-phase dispersion enhancing agent in DOSY NMR 
Medical 
The polymer PVP was used as a blood plasma expander for trauma victims after the 1950's. It 
is used as a binder in many pharmaceutical tablets;
[3]
 it simply passes through the body when 
taken orally. However, autopsies have found that crospovidone does contribute to pulmonary 
vascular injury in substance abusers who have injected pharmaceutical tablets intended for 
oral consumption.
[4]
 The long-term effects of crospovidone within the lung are unknown. 
PVP added to iodine forms a complex called povidone-iodine that possesses disinfectant 
properties.
[5]
 This complex is used in various products like solutions, ointment, pessaries, 
liquid soaps and surgical scrubs. It is known under the trade name Betadine. 
It is used in pleurodesis (fusion of the pleura because of incessant pleural effusions). For this 
purpose, povidone iodine is equally effective and safe as talc, and may be preferred because 
of easy availability and low cost.
[6]
 
Safety 
The U.S. Food and Drug Administration (FDA) has approved this chemical for many uses,
[13]
 
and it is generally considered safe. However, there have been documented cases of allergic 
reactions to PVP/povidone, particularly regarding subcutaneous (applied under the skin) use 
and situations where the PVP has come in contact with autologous serum (internal blood 
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fluids) and mucous membranes. For example, a boy having an anaphylactic response after 
application of PVP-Iodine for treatment of impetigo was found to be allergic to the PVP 
component of the solution.
[14]
 A woman, who had previously experienced urticaria (hives) 
from various hair products, later found to contain PVP, had an anaphylactic response after 
povidone-iodine solution was applied internally. She was found to be allergic to PVP.
[15]
 In 
another case, a man experiencing anaphylaxis after taking acetaminophen tablets orally was 
found to be allergic to PVP.
[16]
 
Povidone is commonly used in conjunction with other chemicals. Some of these, such as 
iodine, are blamed for allergic responses, although testing results in some patients show no 
signs of allergy to the suspect chemical. Allergies attributed to these other chemicals may 
possibly be caused by the PVP instead.  
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             OBJECTIVE AND PLAN OF WORK 
 
Objective of the research work: 
Diclofenac is a non-steroidal anti-inflammatory agent (NSAID) with antipyretic and 
analgesic actions. The anti-inflammatory effects of diclofenac are believed to be due to inhibition 
of leukocyte migration and the enzyme cyclooxygenase (COX-1 and COX-2), leading to the 
peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, 
inhibition of their synthesis is responsible for the analgesic effects of diclofenac. Antipyretic 
effects may be due to action on the hypothalamus, resulting in peripheral dilation, increased 
cutaneous blood flow, and subsequent heat dissipation. The drug shows poor aqueous solubility, 
low permeability and low bioavailability. Thus development of dosage forms that increases the 
solubility and dissolution rate will improve the bioavailability of drug. 
The rational of present research work is to develop and characterize Solid dispersion 
incorporated gel of Diclofenac. Diclofenac solid dispersion was prepared by using PVP and β 
cyclodextrin to increase the solubility, dissolution rate and to improve bioavailability and 
therapeutic efficacy. 
In the present research work an attempt has been made to formulate solid dispersion by 
kneading and solvent evaporation method using PVP and β cyclodextrin, in different ratio are 
prepared solid dispersions is incorporated in to Carbopol 934 and Hpmc gel and evaluated for 
various characterization studies. 
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PLAN OF WORK 
 
The research work was carried out to formulate, evaluate and compare solid dispersion 
incorporated solid dispersion gel of PVP and β cyclodextrin in various proportions using 
carbopol as gelling agent. The following experimental protocol was therefore designed to allow a 
systemic approach to the study. 
 Procurement of drug and raw materials. 
 Preparation of standard curve. 
 Preparation of Solid dispersion. 
 Evaluation of Solid dispersion. 
 Saturation solubility. 
 Drug content determination. 
 In-vitro drug release studies. 
 Preparation of solid dispersion gel. 
o Determination of Gel pH. 
o Spread ability test 
o Viscosity.  
o Cloth staining test. 
o In-vitro drug release studies 
o Skin irritation study 
o Anti-inflammatory study 
o Stability studies. 
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MATERIALS AND INSTRUMENTS 
 
MATERIALS USED: 
The following materials that were either AR/LR grade or best possible grade available 
used for the formulations of solid dispersion gel. 
 
Table No. 01: Materials used for the Research work 
S. No Name Company Name 
1 Diclofenac sodium Nice chemicals pvt ltd 
2 PVP S.D.fine chemicals ltd 
3 β – cyclodextrin S.D.fine chemicals ltd 
4 Carbopol HI media laboratories 
5 TEA 
G.S.K 
Pharmaceuticals 
6 Glycerol Loba chemicals pvt ltd 
7 Methyl paraben HI media laboratories 
8 Hpmc Loba chemicals pvt ltd 
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Table No. 02: Instruments used for the research work 
S. No Instrument Name Company Name 
1 Electronic digital balance Shimadzu, Japan. 
2 Magnetic stirrer 
Genuine Equipment 
Manufactures, Coimbatore 
3 Brook field viscometer 
Brook field engineering labs, 
USA 
4 FT-IR Shimadzu, Japan 
5 Dissolution test apparatus Electro lab, Mumbai, India 
6 Double beam UV/VIS Spectrophotometer ELICO, Mumbai, India 
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PREFORMULATION STUDIES: 
Preformulation study is the first step in the development of dosage forms of a drug 
substance. It is the study of physical and chemical properties of drug particles alone and 
combined with different excipients. The study is useful to find out any interaction between 
drug and excipients and also useful in developing stable and bioavailable dosage forms. The 
drug samples obtained were examined for its appearance and color and results are recorded. 
Appearance of drug: 
The drug samples obtained were examined for its appearance and color and results are 
recorded. 
UV Spectroscopy: 
Preparation of standard solution 
For spectrophotometric method, the standard sample was prepared as follow. 
Diclofenac sodium standard 50 mg was taken and made the volume 100 ml with 0.01N 
NaOH. Sonicated for 10 minutes, filtered the solution and took 2 ml of filtered solution and 
made the volume 100 ml with 0.01 N NaOH. For the spectrophotometric method 2, in the 
above method for standard preparation, 0.01N NaOH Was replaced with methanol. 
FTIR spectroscopy: 
The interaction between drug sample used for the formulation and different excipients 
were studied using FTIR. The FTIR spectrum of pure Diclofenac, polyvinyl pyrrolidone, β-
cyclodextrin physical mixture of drug and PVP, physical mixture of drug and β-cyclodextrin 
were analyzed for compatibility studies. 
Preparation of standard curve of diclofenac with 0.1N HCl (pH 1.2): 
100 mg of Diclofenac was accurately weighed and dissolved in a small portion of 
0.1N HCl in a 100 ml volumetric flask and volume was made to 100 ml. This was primary 
stock solution contained 1000 μg/ml. From this primary stock solution 10 ml was pipette out 
and transferred to 100 ml volumetric flask and volume was made up to 100 ml with 0.1 N 
HCl which contained the concentration of 100 μg/ml. From the second solution 10 ml was 
pipetted out and diluted to 100ml with 0.1 N HCl. From third stock solution aliquots 
equivalent to 2-10 μg/ml (2, 4, 6, 8 and 10ml) were pipette out into a series of 10 ml 
volumetric flask and volume was made up to 10 ml with 0.1 N HCl. The absorbance of this 
solution is measured at 254 nm using UV-Visible spectrophotometer. The calibration curve 
was plotted by taking concentration (μg/ml) on X-axis and absorbance on Y- axis.  
PREPARATION AND EVALUTION 
 
Department Of Pharmaceutics, Nandha College Of Pharmacy, Erode.                                 Page 49 
 
Preparing diclofenac Solid Dispersion  
Initial compatibility studies between Diclofenac and carriers were carried out using 
Fourier Transform Infra Red (FTIR) spectrophotometer, and compatible excipients were used 
for final formulations. 1%diclofenac was used for the study. A physical mixture of 
Diclofenac was prepared by using β cyclodextrin, polyvinyl pyrrolidine carriers in 1:1, 1:2, 
1:3 and 1: 1, 1:3, 1:5 ratios respectively. Solid Dispersions (SDs) of diclofenac were prepared 
using the solvent evaporation, and co-evaporation methods. SD through solvent evaporation 
was prepared by dissolving the drug and carrier in methanol with 15 minutes of stirring, and 
then placed in desiccators for 4 days. The resultant solid dispersion was passed through a 
#120 sieve.  
SD through solvent-evaporation was prepared by dissolving the drug in methanol, and 
the carrier in aqueous media. Subsequently, the organic drug solution was slowly added to the 
aqueous carrier solution followed by stirring at 300 rpm, using a magnetic stirrer at 37ºC for 
24 hrs. The resultant solid dispersion was passed through a #120 sieve.  
Table: Different batches of diclofenac Solid dispersion formulation 
S. No Ingredients F1 F2 F3 F4 F5 F6 
1 Diclofenac sodium (%w/w), g 1 1 1 1 1 1 
2 Polyvinyl pyrrolidone (%w/w), mg - - - 1:1 1:2 1:3 
3 β – Cyclodextrin 1:1 1:3 1:5 - - - 
4 Water : methanol (1:1) Qs Qs Qs - - - 
5 Methanol - - - 10ml 10ml 10ml 
 
Production yield and content determination: 
Prepared solid dispersions were weighed after drying, and process yield was 
calculated. The diclofenac sodium content was determined by UV/Vis spectrophotometer 
assay method at a wavelength of 283 nm. Prepared solid dispersions (300mg) were 
powdered, from which powder equivalent to 50 mg diclofenac was weighed and extracted 
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using three portions of 20mL Phosphate buffer pH 7.2. Each portion was filtered through a 
Whitman’s filter paper and volume was adjusted to 100 ml. After sufficient dilution with 
Phosphate buffer pH 7.2, samples were analyzed spectrophotometrically at 283 nm. 
Diclofenac sodium content was calculated by comparison with standard solution. 
SATURATION SOLUBILITY STUDIES:  
Saturation solubility measurements were assayed through ultraviolet absorbance 
determination at 283 nm using Shimadzu UV-Visible spectrophotometer. The saturation 
solubility studies were carried out for both the unprocessed pure drug and different batches of 
solid dispersion. 10 mg of unprocessed pure drug and diclofenac solid dispersion equivalent 
to 10 mg of diclofenac were weighed and separately introduced into 25 ml stoppered conical 
flask containing 10 ml distilled water. The flasks were sealed and placed in rotary shaker for 
24 hrs at 37°C and equilibrated for 2 days. The samples were collected after the specified 
time interval, and it is filtered and analyzed. The diluted samples were analyzed using UV 
spectrophotometer at 283 nm, the results were analyzed in triplicate and standard deviations 
are reported. 
PERMEATION STUDIES: 
Permeation study is carried out for both unprocessed drug and different batches of 
solid dispersion using cellulose nitrate membrane. The membrane is attached to the diffusion 
cell and then it is dipped in a beaker containing phosphate buffer pH 7.4. The pure drug 
sample and equivalent quantity of lyophilized suspension are weighed and placed in the 
different diffusion cells containing the specified quantity of buffer. The samples were 
withdrawn at specified time intervals for 1 hr and replaced with fresh buffer solution. Finally 
the samples are analyzed using UV spectrophotometer at 283 nm. 
IN-VITRO DRUG RELEASE STUDIES: 
Experimental conditions 
Apparatus: USP (type I) dissolution rate test apparatus. 
Model       : Electro labs, Mumbai.  
Dissolution media: Distilled water. 
Stirring speed: 50rpm 
Temperature: 37±0.5°C 
Sampling intervals: 5, 10, 15, 30, 45 and 60. 
Sampling intervals: 5ml 
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Weight of sample: Equivalent to 100mg. 
Wavelength: 283nm 
Preparing gel formulations  
Carbopol: 
The formulae used to prepare the diclofenac gel formulations. The formulations were 
prepared by soaking carbopol 934 in water for 24 hrs. The solid dispersion containing 1% 
drug was dissolved in ethanol and this solution was added to the above gel with continuous 
stirring Triethanolamine was also added subsequently. The prepared formulations were filled 
in lacquered aluminum collapsible tubes and stored in cool place. 
S. No Ingredients Use Qty of Gel base 
1 Carbopol 934 Gel base 1 g 
2 Distilled water Vehicle 20 ml 
3 Triethanolamine pH adjustment 0.25 ml 
 
Preparation of HPMC: 
Weighed quantities of Hpmc socked in 75ml of water for 24hrs and then add glycerin 
the solid dispersion containing 1% drug was dissolved in ethanol and this dry solution was 
added to above gel with continouns stirring. 
 
S.no Ingredients Use Qty of gel base 
1 Hpmc Gel base 1gm 
2 Distilled water Vehicle 20ml 
3 Triethanolamine pH adjustment 0.25ml 
 
EVALUATION OF DICLOFENAC SODIUM GELS 
The Diclofenac sodium gels were subjected for extensive rheological evaluation, drug 
content estimation, pH measurement, stability study. 
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Visual appearance 
The prepared gels were visually inspected for clarity, color and transparency. The 
prepared gels were also evaluated for the presence of any particles. Smears of gels were 
prepared on glass slide and observed under the microscope for the presence of any particle or 
grittiness. 
 
Rheological studies: In Brookfield viscometer, analog model was used for the studies. First, 
the spindle was dipped into the gel till the notch on the spindle touched the gel surface.100 g 
each of gel I and gel II was used in the study. The spindle no.64 was selected based on the 
viscosity of the gel for both the formulations. This spindle was rotated at 0.5 rpm, and dial 
reading was recorded until 2 consecutive similar readings were obtained. Similarly dial 
readings were recorded at 1.0, 2.5, 5.0, 10.0, 20.0, and 50.0 and up to 100 rpm. As soon the 
sample was sheared at the highest rate, another set of dial readings were recorded by reducing 
the spindle rotation in the decreasing order to the pool the data on the down curve. 
Rheograms were constructed by plotting the dial readings on the X-axis and rpm values along 
the Y-axis. Rheological data were pooled for 
(i) Polymer dispersion in preservative solution (ii) dispersion of polymer and drug in 
preservative solution  
(iii) Dispersion of polymer and humectants in preservative solution (iv) all together. 
Drug content estimation: An accurately weighed 1 gm quantity of the gel was transferred 
into a 250ml stoppered volumetric flask and shaken vigorously with 2x25 ml quantity of 
methanol to extract the drug. The contents were filtered into a 50 ml volumetric flask and 
volume was made up to the mark with methanol. From the above solution, 0.5 ml was pipette 
in to a 25 ml volumetric flask and volume was made up to 25 ml with methanol. 
Finally, the UV absorbance of the resulting solution was measured at 283 nm against the 
blank solution of methanol. Diclofenac Sodium obeys Lambert's beers law in the 
concentration range of 2 -16 μg/ml. A calibration curve was constructed which revealed a 
slope value of 0.0421 and intercept value of 0.0025. These values were used in finding the 
drug content in the formulation after extracting the drug in suitable dilutions and recording 
the absorbance at 283 nm. 
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pH measurement: The pH measurement was carried out by using a calibrated digital type 
pH meter by dipping the glass electrode and the reference electrode completely into the gel 
system so as to cover the electrodes. 
Cloth staining 
This study was undertaken to assess the fabric staining property of the gels. Fabrics of 
different fiber blends ranging from 100% cotton to 100% polyester were procured and stained 
with 0.5 gm gels of Diclofenac and observed for staining after washing. All sample clothes 
were cut into 6 sq inch squares and DTZ gels (0.5 g) were applied in the center of each cloth. 
The stains were air-dried and the clothes left at 50 °C for 48 h to accelerate the drying. After 
leaving them at room temperature for 5 more days (total 1 week), they were washed with 
standard detergent Surf® and water. After air-drying the staining on the sample clothes was 
recorded. 
Swelling Index Study of Topical Gel: 
Swelling of the polymer depends on the concentration of the polymer, ionic strength and the 
presence of water. To determine the swelling index of prepared topical gel, 1 gm of gel was 
taken on porous aluminum foil and then placed separately in a 50 ml beaker containing 10 ml 
0.1N NaOH. Then samples were removed from beakers at different time intervals and put it 
on Dry place for some time after it reweighed. Swelling index was calculated as follows: 
Swelling Index (SW) % = [(Wt – Wo) / Wo] × 100. 
Where, (SW) % = Equilibrium percent swelling, Wt = Weight of swollen gel after time t, 
Wo = Original weight of gel at zero time. 
 In-vitro release studies: The hairless albino rat skin obtained from the discards of the 
animal sacrifice at the pharmacology department in the college was used. The 18 skin was 
soaked in 0.32 N ammonium hydroxide solution for 30 to 35 minutes to remove 
subcutaneous fat and hair. The skin was rinsed well with saline followed by distilled water. 
1 g of the gel was uniformly spread over the rat skin membrane and tied over the donor 
compartment. The skin was placed with stratum corneum facing the donor compartment and 
the dermis facing the receptor compartment containg 100ml distilled water. At hourly 
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intervals, 5ml of sample was withdrawn from the receptor and replaced with fresh 5ml 
distilled water. The 5 ml withdrawn sample was made up to 25 ml with distilled and the 
absorbance was recorded at 280nm. The receptor medium was magnetically stirred for 
uniform distribution and was maintained at a temperature of 37°C ± 0.2°C . 
Skin irritation test: 
 Skin irritation study was carried out on Swiss albino mice weighing 20-30gms. The 
animal was kept under standard laboratory conditions. The animals were housed in 
polypropylene cages with access to laboratory diet. A single dose of diclofenac sodium solid 
dispersion incorporated topical gel was applied once a day for 7days to the left ear of the 
mice with right ear as a control and the site was observed for any sensitivity and reaction. The 
development of erythema was monitored for 7 days using the reported method. 
In vivo Anti-inflammatory effects: 
Procedure and protocol were reviewed by the institutional animal Ethical committee 
and IAEC guidelines were followed for the studies. Anti –inflammatory effects of the 
optimized formulations diclofenac solid dispersion incorporated topical gel and marketed gel 
were evaluated by carrageenan included paw edema method developed in Westar rates by 
winter et al.Albino rates of Wister strains of either sex between 140-170 grams were selected 
for the studies. The animals were kept under standard laboratory conditions at a temperature 
of 25 ± 1ºc and relative humidity of 55 ± 5%.the animals were housed in poly propylene 
cages, with free access to standard laboratory diet. 
Group 1:  control 
Group 2: carrageenan 
Group 3: diclofenac sodium solid dispersion incorporated topical gel 
Group 4: marketed available gel 
             25 mg and 50 mg of respective formulation of diclofenac sodium solid dispersion 
incorporated gel were applied to the right paw half an hour before carrageenan was injected 
subcutaneously. Paw edema was induced by injecting 0.1% w/v dispersion of carrageenan in 
distilled water. Paw volume was measured by plethysmometer at different time intervals. The 
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amount of paw swelling was determined time to time and expressed as percent edema 
.Percent inhibition of edema produced by each formulation-treated group was calculated 
against the respective control group. Test was carried out for a period of 12 hours and % 
inhibition of edema was calculated by using the following formula. Result of these studies 
were compared using dunnet test of one-way analysis of variance 
 
Where v = paw volume at 30min interval after the 0.1ml of 1% carrageenan injection. 
V1= initial paw volume 
 The average paw swelling in this drug test group was compared with that of control rats and 
percentage inhibition was determined using following equation  
% of inhibition of edema= [1-vt/vc] ×100 
   VT= mean inflammation of test group. 
   VC=mean inflammation of test group.  
Stability study 
Stability studies for Diclofenac sodium gels were carried out as per ICH guidelines.  
The gel samples were stored at 25 C, 60% RH and 40 C,70% RH, in stability chambers for a 
period of 6 months, samples were drawn at regular interval for stability analysis. At the end 
of 6 months assay was carried out to find out if there is any interaction between the drug and 
other ingredients of the formulation upon storage. 
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PREFORMULATION STUDIES: 
Appearance of drug substance: 
The drug sample obtained was appeared as a white to slightly yellowish crystalline powder. 
UV-spectroscopy: 
The UV spectrum analysis of diclofenac sodium was carried out using methanol as blank and 
the λ max of diclofenac was found to be 283 nm. 
Fig. 1 UV spectrum of Diclofenac 
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FTIR spectroscopy: 
The FTIR spectra of Diclofenac, PVP, β - cyclodextrine, physical mixture 1, physical 
mixture 2, Formulation is recorded to check any interaction between drug and polymer. The 
characteristic peak obtained after FTIR indicates that there is no chemical interaction between 
drug, β-cyclodextrine, and PVP. 
Table No. 05: Interpretation of IR spectrum of Diclofenac 
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IR Spectrum of Diclofenac  
Fig No. 2 
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FTIR - Spectrum of PVP 
Fig no. 3 
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FT-IR Spectrum of β cyclodextrin 
Fig no. 4 
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FT-IR Spectrum of Diclofenac + Cyclodextrin 
Fig no.5 
 
 
 
 
FT-IR Spectrum of Diclofenac + PVP 
Fig no.6 
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Preparation of Standard Curve: 
Table no. 2: Standard curve of Diclofenac sodium 0.1N HCL 
 
 
S. No 
Concentration (μg/ml) Absorbance at 283 
1 
8 0.080 
2 
12 0.195 
3 
16 0.258 
4 
20 0.328 
5 
24 0.406 
 
Fig No.7 Standard curve of Diclofenac Sodium 
 
 
DRUG CONTENT DETERMINATION 
The percentage drug content present in all the formulation was analyzed using UV-
spectroscopy. All formulation shows a percentage content between 98.0% to 100% range 
which is acceptable according to united state pharmacopoeia. 
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Table No. 03: Estimation of drug content 
S.  No 
Formulation Percentage  Drug content 
1 
F1 78% 
2 
F2 80% 
3 
F3 95% 
4 
F4 81% 
5 
F5 93% 
6 
F6 90% 
 
SATURATION SOLUBILITY STUDIES: 
The solubility studies are carried out for both unprocessed drug and different batches 
of solid dispersion. All the formulated solid dispersion shows maximum solubility than the 
unprocessed drug and the formulation f3 & f5 shows maximum solubility. 
 
Table No. 04: Solubility study data 
S.  No Formulation Solubility (μg/ml) 
 Unprocessed drug 9.59 
1 F1 25 
2 F2 80 
3 F3 125 
4 F4 72 
5 F5 105 
6 F6 90 
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Fig No.8 Solubility study 
 
 
 
RELEASE PROFILE FOR SOLID DISPERSION: 
Time 
(mins) 
 
PD 
(1%W/W) 
 
1:1 
(diclo+β-
CD) 
1:2 
(diclo+β-
CD) 
1:3 
(diclo+β-
CD) 
1:1 
(diclo+pvp) 
1:3 
(diclo+pvp) 
1:5 
(diclo+pvp) 
5 11.32 15.17 36.23 47.48 30.76 38.21 20.03 
10 12.02 25.24 48.46 59.84 38.45 47.70 27.14 
15 12.89 34.82 57.48 73.28 42.16 69.36 40.85 
30 13.90 47.78 69.80 80.39 51.33 78.71 49.77 
45 14.01 55.96 75.96 93.12 63.81 86.54 55.52 
60 14.93 71.36 87.51 96.59 75.47 92.98 63.29 
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Fig No.9 Release properties of solid dispersion 
 
 
EVALUATION OF SOLID DISPERSION INCORPORATED GEL  
Spreadability test  
            Two glass slides of standard dimensions (2cm X 5cm) were selected. The gel 
formulation of which spread ability has to be determined was placed over one of the slides; 
the other slide was placed on the top of the gel such that the gel was sandwiched between the 
two slides.100gm was placed upon the upper slide and the gel between the two slides is 
pressed uniformly to form thin layer. The two slides in position were fixed to stand (at angle 
45º) without any disturbance and in such a way that only the lower slide was held firmly by 
the clamp following the upper slide to travel the distance at 0.5 cm under the direction of 
weight was noted. The weight was removed and the excess of gel adhering to the slide was 
scrapped off. The experiment was repeated and mean time taken for three such 
determinations was calculated. The results were recorded.                                                                    
  Spreadability calculated using the formula, S =    
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       Whereas,           S = spreadability. 
                                     M = weight given to upper slide. 
                                     L = distance traveled by glass slide. 
                                     T = time taken 
Carbopol:  
FORMULATION SPREDABILITY 
(cm) 
F1 6.9 
F2 5.6 
 
 
HPMC: 
FORMULATION SPREDABILITY (cm) 
F4 5.4 
F4 5.4 
 
 
Cloth staining: 
This study is very important to ascertain the patient compliance of the gels. Patients 
generally resist gels as they stain clothes. It was observed that all the four gels did not stain 
any of the fibre blends tested, even after prolonged exposure and accelerated drying. It could 
be concluded that none of the four gels stained any of the tested fibres. 
 
Swelling Index Study of Topical Gel 
From these data we found, topical gel prepared from carbopol polymer has greater 
percent swelling index as compare to topical gel prepared from Hydroxy Propyl Methyl 
Cellulose. Table shows swelling index study data and Fig, shows graphical representation of 
swelling index study. 
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Carbapol: 
 
Time (hrs.) 
Swelling Index (%Sw) 
F1 F2 
1 13.67 11.00 
2 20.30 19.98 
4 44.66 47.86 
6 69.19 64.36 
8 83.07 72.12 
10 97.33 89.07 
                                                                                                                                                  
HPMC: 
Time (hrs.) 
Swelling Index (%Sw) 
F3 F4 
1 09.02 10.4 
2 14.55 15.67 
4 20.70 22.56 
6 30.91 34.22 
8 42.18 43.79 
10 56.58 58.01 
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Homogeneity:  
Gels were tested for homogeneity by visual inspection after the gels have been set in 
the container. They were tested for their appearance and presence of any aggregate. 
 
VISCOSITY MEASUREMENT 
FORMULATION VISCOSITY cp pH HOMOGENICITY 
F1 35310 7.4 Good 
F2 35129 7.4 Good  
F3 23561 7.4 Good 
F4 21972 7.4 Good 
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In–vitro Drug Diffusion Study: 
From these data we have found that the prepared topical gel for carbapol releases 
95.69% in in-vitro diffusion study over a period of 24hrs. 
 FG 1: 
Time in 
Hrs. 
Absorbanc
e 
Concentratio
n 
Amt of drug 
dissolved in 
mg/ml 
Cumulative 
amt of drug 
dissolved in 
900ml 
Cumulative 
%Drug 
released 
0.5 0.031 0.71 0.0177 15.99 2.45 
1 0.078 1.78 0.0447 40.28 5.62 
2 0.115 2.63 0.0659 59.47 10.67 
3 0.148 3.39 0.0848 76.63 19.41 
4 0.201 4.61 0.1152 104.15 30.68 
5 0.237 5.43 0.1358 122.96 38.89 
6 0.296 6.78 0.1697 153.68 47.92 
7 0.354 8.11 0.2029 183.95 54.44 
8 0.397 9.10 0.2276 206.54 63.63 
9 0.412 9.44 0.2362 214.74 70.53 
10 0.523 11.99 0.2998 272.28 75.57 
21 0.698 35.558 0.8889 808.43 84.85 
24 0.834 42.486 1.0622 956.91 95.69 
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From these data we have found that the prepared topical gel for carbapol releases 88.81% in 
in-vitro drug diffusion study over a period of 24hrs. 
 
FG 2: 
 
Time 
in hrs 
Absorbance Concentration Amt of drug 
dissolved in 
mg/ml 
Cumulative 
amt of drug 
dissolved in 
900ml 
Cumulative 
% drug 
released 
0.5 0.021 1.09 0.0272 24.5287825 2.53 
1 0.049 2.49 0.0624 56.2185431 6.89 
2 0.093 4.737 0.1184 106.776363 14.7 
3 0.169 8.60 0.2152 194.12 19.77 
4 0.267 13.60 0.3400 306.88 24.86 
5 0.338 17.21 0.4304 388.94 32.83 
6 0.416 21.19 0.5298 479.20 40.81 
7 0.472 24.04 0.6011 544.45 48.92 
8 0.551 28.06 0.7017 636.20 55.56 
9 0.61 31.07 0.7768 705.23 62.67 
10 0.653 33.26 0.8316 755.74 69.98 
21 0.697 35.50 0.8876 808.17 80.82 
24 0.774 39.42 0.9857 888.00 88.81 
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From these data we have found that the prepared topical gel for Hpmc releases 74.52% in in-
vitro drug diffusion releases over a period of 24hrs. 
FG 3: 
 
time in 
Hrs 
absorbance concentration amt of drug 
dissolved in 
mg/ml 
Cumulative 
amt of drug 
dissolved in 
900ml 
cumulative % 
Drug 
Released 
0.5 0.031 0.71 0.0177 15.99 3.55 
1 0.078 1.78 0.0447 40.28 8.95 
2 0.115 2.63 0.0659 59.47 13.21 
3 0.148 3.39 0.0848 76.63 17.02 
4 0.201 4.61 0.1152 104.15 23.14 
5 0.237 5.43 0.1358 122.96 27.32 
6 0.296 6.78 0.1697 153.68 34.15 
7 0.354 8.11 0.2029 183.95 40.87 
8 0.397 9.10 0.2276 206.54 45.89 
9 0.412 9.44 0.2362 214.74 47.72 
10 0.523 11.99 0.2998 272.28 60.50 
21 0.598 13.71 0.3428 311.80 69.28 
24 0.649 14.88 0.372 335.34 74.52 
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From these data we have found that the prepared topical gel for Hpmc releases 71.19% in in-
vitro drug diffusion study over a period of 24hrs. 
FG 4: 
 
time in 
Hrs 
Absorbance concentration amt of drug 
dissolved in 
mg/ml 
Cumulative 
amt of dru 
dissolved in 
900ml 
cumulative 
% Drug 
Released 
0.5 0.03 0.68 0.0172 15.48 3.44 
1 0.059 1.35 0.0338 30.48 6.77 
2 0.113 2.59 0.0647 58.41 12.98 
3 0.149 3.41 0.0854 77.12 17.13 
4 0.211 4.83 0.1209 109.29 24.28 
5 0.243 5.57 0.1393 126.04 28.01 
6 0.326 7.47 0.1869 169.15 37.59 
7 0.372 8.53 0.2133 193.26 42.94 
8 0.43 9.86 0.2465 223.62 49.69 
9 0.498 11.42 0.2855 259.21 57.60 
10 0.553 12.68 0.3170 287.97 63.99 
21 0.594 13.62 0.3405 309.95 68.87 
24 0.62 14.22 0.3555 320.35 71.19 
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Skin irritation test: 
S.no Group Score after(days) Mean 
score 
±SD 
1 2 3 5 7 
1 Gel 2 2 2 2 1 1.8±0.53 
2 Mp 3 2 3 3 2 2.6±1.03 
 
Skin irritation study was performed to conform the safety of the optimized diclofenac 
solid dipersion incorporated gel .van-abbe et al mentioned that valuve between 0and 9. 
It indicates that the applied formulation is generally not an irritant to human skin.the 
mean skin irritation score for optimized diclofenac solid disepersion incorporated gel 
formulation and marketed gel was found to be 1.8±0.53 and2.6±1.03 respectively optimized 
diclofenac solid dispersion incorporated gel was shown less irritation profle when compared 
with marketed product.  
 
Anti-inflammatory effects: 
 
 
 
 
 
 
GROUPS At 0 hr At 4 hrs At 8 hrs At 24 hrs 
CONTROL 4.56±0.081 4.56±0.543 4.52±0.024 4.48±0.109 
STANDARD 4.97±0.034 4.88±0.251
**
 4.72±0.018
**
 4.67±0.052 
TEST 5.09±0.100 4.91±0.092
**
 4.83±0.62
**
 3.96± 0.030
***
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Stability test: 
  
 
 
Month 0 2 4 6 
Room Tempt 
(25±1
0
C) 
100% 99% 98% 98% 
Oven Tempt 
(40±1
0
C) 
100% 98% 97% 97% 
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SUMMARY AND CONCLUSION 
 
The diclofenac sodium shows poor aqueous solubility and oral administration causes 
irritation of gastro intestinal tract, lack of bioavailability. The aim was to investigate the 
potential of diclofenac loaded solid dispersion based gel for topical delivery in order to 
improve the solubility, thereby increasing the bioavailability of drug. This alternate topical 
route eliminates oral side effects, increases patient compliance, avoids high first pass 
metabolism and maintains the plasma drug level for a longer period of time. 
Solid dispersion incorporated diclofenac gel are thermodynamically stable. The solid 
dispersions are prepared by kneading method (β cyclodextrin) and solvent evaporation 
technique (PVP), followed by being incorporated into Carbopol 934 and HPMC based gel 
matrix to form solid dispersion incorporated diclofenac solid dispersion incorporated tropical 
gel. 
Among the solid dispersion, formulation which showed highest release was selected 
to incorporate with Carbopol 934 and HPMC base to form gel. On the basis of swelling index 
invitro release studies, spreadability, viscosity, homogenization, saturation solubility study, 
we selected FG1 formulation which contained the combination of Diclofenac sodium, 
βcyclodextrin solid dispersion incorporated, carbopol 934 Gel for the use of invitro and in 
vivo studies. The optimized gel (FG1) was taken for their invitro skin permeation study, in 
vivo anti-inflammatory, effects and skin irritation study. 
The invitro and in vivo study for optimized diclofenac solid dispersion incorporated 
gel FG1 were compared with Marketed gel, revealed a significant increase in skin permeation 
profile and anti-inflammatory effects for optimized gel. The percent inhibition value of 
optimized gel after 12 hours of administration was found to be 5.22% as compared with 
5.41% for Marketed gel. From invitro and in vivo data it can be concluded that optimized 
carbopol gel containing diclofenac solid dispersin have great potential for topical delivery. 
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